

Published in final edited form as:

Biochim Biophys Acta. 2011 November ; 1807(11): 1398–1413. doi:10.1016/j.bbabi.2011.06.016.

The cytochrome *bd* respiratory oxygen reductases

Vitaliy B. Borisov^{a,*}, Robert B. Gennis^b, James Hemp^b, and Michael I. Verkhovsky^c

^aBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russian Federation ^bDepartment of Biochemistry, University of Illinois, 600 South Mathews Street, Urbana, IL 61801, USA ^cHelsinki Bioenergetics Group, Institute of Biotechnology, University of Helsinki, PB 65 (Viikinkaari 1), 00014, Helsinki, Finland

Summary

Cytochrome *bd* is a respiratory quinol:O₂ oxidoreductase found in many prokaryotes, including a number of pathogens. The main bioenergetic function of the enzyme is the production of a proton motive force by the vectorial charge transfer of protons. The sequences of cytochromes *bd* are not homologous to those of the other respiratory oxygen reductases, i.e., the heme-copper oxygen reductases or alternative oxidases (AOX). Generally, cytochromes *bd* are noteworthy for their high affinity for O₂ and resistance to inhibition by cyanide. In *E. coli*, for example, cytochrome *bd* (specifically, cytochrome *bd*-I) is expressed under O₂-limited conditions. Among the members of the *bd*-family are the so-called cyanide-insensitive quinol oxidases (CIO) which often have a low content of the eponymous heme *d* but, instead, have heme *b* in place of heme *d* in at least a majority of the enzyme population. However, at this point, no sequence motif has been identified to distinguish cytochrome *bd* (with a stoichiometric complement of heme *d*) from an enzyme designated as CIO. Members of the *bd*-family can be subdivided into those which contain either a long or a short hydrophilic connection between transmembrane helices 6 and 7 in subunit I, designated as the Q-loop. However, it is not clear whether there is a functional consequence of this difference. This review summarizes current knowledge on the physiological functions, genetics, structural and catalytic properties of cytochromes *bd*. Included in this review are descriptions of the intermediates of the catalytic cycle, the proposed site for the reduction of O₂, evidence for a proton channel connecting this active site to the bacterial cytoplasm, and the molecular mechanism by which a membrane potential is generated.

Keywords

metabolism; molecular bioenergetics; oxidoreduction; bacterial physiology; microbe; disease

1. Diversity of respiratory oxygen reductases

Respiratory oxygen reductases (terminal oxidases) are enzymes at the end of the respiratory chains of organisms which couple the oxidation of a respiratory substrate (one-electron donor, cytochrome *c*, or two-electron donor, quinol (QH₂)) to the four-electron reduction of O₂ to water. There are three families of oxygen reductases (Fig. 1).

© 2010 Elsevier B.V. All rights reserved.

*To whom correspondence should be addressed: Tel.: +7 495 9395149; fax: +7 495 9393181. bor@genebee.msu.su.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1.1 Heme-copper family

The first, most extensively studied family comprises the heme-copper oxygen reductases. They have a binuclear O₂-reduction site composed of a high spin heme (*a*₃, *o*₃, or *b*₃) and a copper ion (Cu_B), and these enzymes generate a PMF via a “proton pump” mechanism [1–7]. The PMF is utilized for various biosynthetic activities (e.g., ATP production), solute active transport and mechanical movement (e.g., flagellar rotation). The heme-copper family of oxygen reductases includes both cytochrome *c* oxidases and quinol oxidases. Most of the heme-copper oxygen reductases are members of one of three distinct subfamilies: A, B, and C [8,9]. The A subfamily includes the mitochondrial cytochrome *c* oxidases as well as many prokaryotic cytochrome *c* oxidases and quinol oxidases. Enzymes in the A-subfamily utilize at least two proton pathways to deliver protons to the active site or for proton pumping. The B subfamily includes a number of oxygen reductases from extremophilic prokaryotes, such as the *ba*₃-type oxygen reductase from *T. thermophilus* [10]. The enzymes of the C subfamily are all *cbb*₃-type oxidases [11]. Recently, it has been shown that the enzymes from the B and C subfamilies utilize only one proton-conducting input pathway [10,12]. High-resolution x-ray crystal structures of the heme-copper oxidases from all three subfamilies have been reported [11,13–23].

1.2 Alternative oxidase (AOX) family

The second family of respiratory oxygen reductases comprises cyanide-resistant AOX found in mitochondria of higher plants, fungi and protists as well as in prokaryotes and some animal species [24]. In plants, this is a homodimeric enzyme associated with the matrix side of the inner mitochondrial membrane. AOX uses UQH₂, but not cytochrome *c*, as the electron donor, and contains a non-heme di-iron carboxylate active site for O₂ reduction.

AOX does not produce a PMF, and is not coupled to transmembrane charge transfer. However, AOX is responsible for heat generation in some tissues, and plays a role in the regulation of energy metabolism, facilitating turnover of the TCA cycle, protection against oxidative stress, and homeostasis. To date, no high-resolution AOX structure has been reported, but crystals that diffract to better than 3.0 Å have been described [25].

1.3 Cytochrome *bd*-family

The third family of oxygen reductases comprises cytochromes *bd*. These are quinol oxidases found in a wide variety of prokaryotes. They show no sequence homology to any subunit of heme-copper family members or AOX and do not contain any copper or non-heme iron [26–33]. This two-subunit integral membrane protein (subunits I and II) contains three hemes, *b*₅₅₈, *b*₅₉₅ and *d*, and it is generally thought that hemes *b*₅₉₅ and *d* form a di-heme site for the reduction of O₂ (Fig. 2) [34–43]. Unfortunately, no X-ray structure of any *bd*-type oxygen reductase has been reported. Cytochrome *bd* generates a PMF by transmembrane charge separation, but does so without being a “proton pump” [41,44–50]. In a number of organisms, the *bd* oxygen reductase is induced under O₂-limited conditions as well as under other growth conditions that can be considered stressful, such as Fe deficiency [51–54]. All known members of the *bd*-family of oxygen reductases are quinol oxidases, most commonly using ubiquinol or menaquinol as substrates.

Analysis of prokaryotic genomes shows that many aerobic prokaryotes do not contain any member of the *bd*-family, but contain only heme-copper oxygen reductases. However, there are a number of prokaryotes that encode more than one *bd*-family member, for example, two: *E. coli* [53,55], *Bacillus subtilis* [56]; three: *Vibrio cholerae* [57]; and as many as six *bd*-type oxygen reductases: some *Acidithiobacillus* strains. Organisms that express one or more *bd*-type oxygen reductases, usually also possess at least one heme-copper oxygen

reductase. However in some cases (e.g., *Lactobacillus plantarum* [58], *Zymomonas mobilis* [59], the two *Thermoplasma* strains [60]) cytochrome *bd* is the only oxygen reductase.

1.3.1 The Q-loop—The hydrophilic region of subunit I connecting transmembrane helices 6 and 7, facing the outside of the prokaryotic cell, has been implicated as part of the quinol binding site [61–66], and this is referred to as the “Q loop”. Some of the *bd*-family oxygen reductases have an insert in the C-terminal portion of the Q-loop and, hence, have a “long Q-loop”, e.g., enzymes isolated from *Escherichia coli* and *Azotobacter vinelandii* [67,68]. The majority of *bd*-type oxygen reductases have a “short Q-loop”, e.g., the enzyme isolated from *Bacillus stearothermophilus* [67–69]. It is not clear what the functional consequences are, if any, from this difference in the size of the Q loop.

1.3.2 Cyanide insensitive oxidases (CIO)—An anecdotal observation is that some of the “short Q-loop” oxygen reductases appear to have an altered heme content, in which the amount of heme *d* is significantly reduced (or totally missing) and is replaced by a heme *b*. This appears to be the case for a *B. subtilis* cytochrome *bd* [70]. When these enzymes, with a low content of heme *d*, have been characterized in bacterial membranes, respiration continues even in the presence of 1 mM KCN [71], but the membranes do not have the spectroscopic signature of heme *d* (a peak in the reduced form near 630 nm) [71–75]. As a result, these enzymes have been called cyanide insensitive oxidases (CIO) [73]. Examples are *P. aeruginosa* [71–73,76], *P. putida* [77], *P. pseudoalcaligenes* [74], *Staphylococcus carnosus* [78], *C. jejuni* [75], *Z. mobilis* [59]. On the contrary, using low temperature absorption spectroscopy, EPR and mass spectrometry, Mogi et al. [79] reported that CIO in the membranes from *G. oxydans* has the same heme contents present in a classical cytochrome *bd*, although reveals unique spectroscopic and ligand-binding properties. Whether the CIO heme composition is strain- and/or growth-specific, or the heme spectral features were not detected due to a very low enzyme concentration in the tested membranes remains to be studied. It is now clear that CIOs are *bd*-family oxygen reductases.

cioA and *cioB* genes which encode CIO in *P. aeruginosa* and *P. pseudoalcaligenes* were sequenced [73,74]. They comprise the *cio* operon. CioA and CioB are homologous to subunits I and II of cytochrome *bd*-I from *E. coli* and the *bd*-oxidase from *A. vinelandii* [73]. Histidine and methionine residues identified in cytochrome *bd*-I from *E. coli* as the axial ligands to heme *b*₅₅₈ and heme *b*₅₉₅ are conserved [73]. It was proposed that the slight differences in sequence and structure of the CydB subunit are responsible for cyanide resistance [78]. It is of interest to note that cytochrome *bd* of the cyanobacterium *Synechocystis* sp. PCC 6803 appeared to be structurally related to CIO [80]. To date, no CIO has been purified and characterized, primarily because these enzymes appear to be particularly labile. At low O₂ tensions, the opportunistic pathogen *P. aeruginosa* synthesizes HCN as a metabolic product at concentrations of up to 0.3 mM [81]. Under these conditions, the heme-copper oxidases are inhibited. CIO likely has a role in allowing aerobic respiration under cyanogenic and microaerobic growth conditions [71,73,82]. Cyanide can be found in tissues infected with *P. aeruginosa* [83] that is consistent with the conclusion that CIO is required for full pathogenicity of *P. aeruginosa* in the cyanide-mediated paralytic killing of nematodes [84]. Mutation or overexpression of the *cioAB* genes of *P. aeruginosa* leads to temperature sensitivity for growth, difficulty exiting stationary phase, abnormal cell division and multiple antibiotic sensitivity [85].

There is no distinguishing feature in the sequences of the genes that allows one to differentiate CIO from other cytochrome *bd* family members. It is not yet clear whether the “short Q-loop” is a requirement for having the CIO phenotype or under what conditions such enzymes may or may not contain a stoichiometric content of heme *d*.

2. Physiological functions

The bioenergetic function of cytochrome *bd* is to conserve energy in the form of $\Delta\mu_{\text{H}^+}$ [41,45–50], although the H^+/e^- ratio is 1, half the value of the A-subfamily heme-copper oxygen reductases such as the mitochondrial cytochrome *c* oxidase or cytochrome *bo*₃ from *E. coli* because the *bd*-type oxygen reductases do not pump protons [45,49,50].

Apart from PMF generation, cytochrome *bd* endows bacteria with a number of vitally important physiological functions. Cytochrome *bd* facilitates both pathogenic and commensal bacteria to colonize O₂-poor environments [86–89], serves as an O₂ scavenger to inhibit degradation of O₂-sensitive enzymes such as nitrogenase [90–98], and support anaerobic photosynthetic growth [99]. It is of interest to note that *bd*-type oxygen reductases predominate in the respiratory chains of bacteria that cause such diseases as bacillary dysentery [100], brucellosis [88,101], tuberculosis [87], pneumonia, life-threatening sepsis, meningitis [102], as well as *Salmonella* [103,104], *Bacteroides* [86], and *Listeria monocytogenes* [105] infections. There is a positive correlation between virulence of bacterial pathogens responsible for these diseases and level of cytochrome *bd* expression. Cytochrome *bd* enhances bacterial tolerance to nitrosative stress [106–111], contributes to mechanisms of detoxification of hydrogen peroxide in *E. coli* [112–114], suppresses extracellular superoxide production in *Enterococcus faecalis* [115], and is involved in the degradation of aromatic compounds in *Geobacter metallireducens* [116]. The *A. vinelandii* cytochrome *bd* might be directly involved in energizing Fe-siderophore transport or in reduction of Fe(III)-chelates and, thus, metal liberation in the cytoplasm [117]. As a source of oxidizing power, cytochrome *bd*-I in *E. coli* can support disulfide bond formation upon protein folding catalyzed by the DsbA-DsbB system [118], as well as the penultimate step of heme biosynthesis, the conversion of protoporphyrinogen IX into protoporphyrin IX, catalyzed by protoporphyrinogen IX oxidase [119].

The expression and membrane content of cytochrome *bd* in *E. coli* increase not only at low O₂ concentrations [120–122], but also under other stressful conditions, such as alkalization of the medium [123], high temperature [124,125], the presence of poisons in the environment (for instance, cyanide [126,127]), uncouplers-protonophores [123,128,129] and high hydrostatic pressure [130,131]. *E. coli* mutants defective in cytochrome *bd* are sensitive to H₂O₂ [125], zinc [127,132] and a self-produced extracellular factor that inhibits bacterial growth [133,134]. *E. coli* mutants that cannot synthesize cytochrome *bd* are also unable to exit from the stationary phase and resume aerobic growth at 37 °C [135,136].

Since cytochrome *bd* is found only in prokaryotes, including a number of human pathogens, the enzyme may be of interest as a drug target. A search for specific inhibitors of the *bd*-type oxygen reductases, which could be used in clinical practice, has been started [137,138]. An alternative, “positive” potential use of cytochrome *bd* might be for a therapy of respiratory chain deficiencies. It is known that mutations in genes encoding structural subunits of cytochrome *bc*₁ complex and cytochrome *c* oxidase can lead to severe neuromuscular and non-neuromuscular human diseases [139,140]. At the same time, it was reported that mixing purified cytochrome *bd*-I from *E. coli* with myxothiazol-inhibited bovine heart submitochondrial particles restores up to half of the original NADH oxidase and succinate oxidase activities in the absence of exogenous ubiquinone analogs [141]. Respiration bypassing the *bc*₁ complex is saturated at amounts of added *bd*-oxidase similar to that of other natural respiratory components in submitochondrial particles. Bacterial cytochrome *bd*-I tightly binds to the mitochondrial membrane and functions as an intrinsic component of the chimeric respiratory chain [141]. Thus, cytochrome *bd*, as well as AOX [142–144], might compensate for respiratory chain deficiencies in human cells.

3. Inhibitors

Table 1 shows the effect of different inhibitors on the respiratory activity of cytochrome *bd* from some bacteria. Quinol oxidase inhibitors can be divided into two groups: Q-like compounds acting at the Q binding site and heme ligands (e.g., cyanide, azide or NO) acting at the O₂ binding/reducing site. A specific feature of cytochrome *bd* is that it is much less sensitive to cyanide and azide than a heme-copper oxygen reductase like cytochrome *bo₃* [27]. The lower sensitivity of cytochrome *bd* to anionic heme ligands may be a result of an elevated electron density on the central ion of iron due to breaking the conjugate π -electron structure in the *d*-type porphyrin ring and/or may point to a more hydrophobic environment of the O₂-reducing site. It was reported that cytochrome *bd*-I in *E. coli* is a bacterial membrane target for a cationic cyclic decapeptide gramicidin S (IC₅₀ ~5.3 μ M, Table 1), although it has been generally accepted that the main target of gramicidin S is the membrane lipid bilayer rather than the protein components [145]. This finding can provide a new insight into the molecular design and development of novel gramicidin S-based antibiotics. The effect of gramicidin S on cytochrome *bd*-I and some other membrane-bound proteins could be the alteration of the protein structure through binding to its hydrophobic protein surface [145].

4. Genetics

4.1. Genes in *E. coli* encoding the protein subunits and assembly factors

Of the *bd* family, the best studied oxidase is cytochrome *bd*-I from *E. coli*. The two subunits of cytochrome *bd*-I are encoded by the *cydAB* operon [28,146,147] located at 16.6 min on the *E. coli* genetic map [146,148]. It was cloned [149] and sequenced [28]. The molecular weights of subunit I (CydA) – 57 kDa, and subunit II (CydB) - 43 kDa, determined by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis [26], are consistent with those of 58 and 42.5 kDa based on DNA sequence [28]. The enzyme subunits carry three hemes: *b₅₅₈*, *b₅₉₅*, and *d* [34,150]. Heme *b₅₅₈* is located on subunit I (CydA), whereas hemes *b₅₉₅* and *d* are likely to be in the area of the subunit contact [151]. CydA can be expressed and purified without CydB using mutant strains defective in *cydB* [152]. The purified CydA retains heme *b₅₅₈* but lacks hemes *b₅₉₅* and *d* [152]. In addition to the *cydAB* operon, the two other genes, *cydC* and *cydD* of the *cydCD* operon located at 19 min on the *E. coli* genetic map [132,153,154], are essential for the assembly of cytochrome *bd*-I [153–156]. CydC and CydD however are not subunits of cytochrome *bd*-I. It was shown that *cydCD* encodes a heterodimeric ATP-binding cassette-type transporter that is a glutathione transport system [157]. An orphan protein, YhcB, was proposed to be a third subunit of cytochrome *bd*-I [158], but this was later shown not to be the case [159].

In *E. coli*, a second cytochrome *bd* (*bd*-II) encoded by *cyxAB* genes (also named *appBC* or *cbdAB*) was identified [160]. The *cyxAB* genes, located at 22 min on the *E. coli* genetic map, are upstream from pH 2.5 acid phosphatase (*appA*) gene [160]. The *cyxAB* and *appA* genes constitute the complex operon. The *cyxA* and *cyxB* genes encode 58.1 kDa and 42.4 kDa integral membrane proteins, respectively. The deduced amino acid sequences of *cyxA* and *cyxB* genes reveal homologies of 60 and 57%, respectively, to subunit I (CydA) and subunit II (CydB) of cytochrome *bd*-I [160].

4.2. Regulation of gene expression in *E. coli* and other bacteria

Cytochrome *bd*-I is expressed by *E. coli* when the O₂ tension is low [120–122,161,162]. The expression of the *cydAB* operon is controlled by the two global transcriptional regulators, Arc and Fnr [121,161,163–169]. Arc is a two-component regulatory system that includes ArcA, a cytosolic response regulator, and ArcB, a transmembrane histidine kinase sensor. ArcA controls several hundred genes [170] and responds to the oxidation state of the Q pool

which is sensed by ArcB [171]. ArcB is activated in response to the transition from aerobic to microaerobic growth and remains active during anaerobic growth. Upon stimulation, ArcB autophosphorylates and then transphosphorylates ArcA [171,172]. Under microaerobic conditions (i.e., O₂ tension of 2 to 15% of air saturation), the increased level of phosphorylated ArcA activates the *cydAB* operon [173]. Another global regulator, Fnr (an O₂-labile transcription factor regulating hundreds of genes), controls induction of anaerobic processes in *E. coli* [174,175]. The Fnr protein has a Fe-S cluster which serves as a redox sensor. The levels of the Fnr protein are similar under both aerobic and anaerobic conditions [165,176], but the protein is active only during anaerobic growth. The active Fnr protein represses *cydAB* operon during the transition to anaerobic conditions (i.e., O₂ tension of less than 2% of air saturation) [167,168,176].

Expression of *cyxAB-appA* operon (coding for cytochrome *bd-II* in *E. coli*) is induced by phosphate starvation and entry into a stationary phase [177]. The *cyxAB* genes can also be induced by anaerobic growth and this induction is controlled by transcriptional regulators AppY and ArcA but independent of Fnr, in contrast to *cyd* operon [177,178]. Cytochrome *bd-II* is likely to function under even more-O₂-limiting conditions than cytochrome *bd-I* [178]. Cytochrome *bd-II* has been partially purified [179], and contains two subunits by SDS-PAGE with apparent molecular weights 43 kDa (subunit I) and 27 kDa (subunit II). These subunits show no cross-reactivity to subunit-specific polyclonal antibodies directed against the subunits of cytochrome *bd-I* [179]. The spectral properties of cytochrome *bd-II* closely resemble those of cytochrome *bd-I*. Of the quinols tested as substrates, cytochrome *bd-II* utilizes menadiol as the preferred substrate (although ubiquinol-1, the most efficient *in vitro* substrate for cytochrome *bd-I*, was not tested). TMPD oxidase activity of cytochrome *bd-II* is much more sensitive to cyanide than that of cytochrome *bd-I* [179]. It was reported that though the electron flux through cytochrome *bd-II* can be significant, the enzyme does not contribute to the generation of the PMF [180]. Shepherd et al. [181] proposed that under conditions of an apparently fully uncoupled mode, *E. coli* can create PMF by means of consumption of intracellular protons in synthesis of γ -aminobutyric acid (GABA) and the generation of a pH gradient via uptake of glutamate and export of GABA by glutamate/GABA antiport.

In *A. vinelandii*, regulation of cytochrome *bd* expression is achieved by CydR (an Fnr homologue), which represses transcription of the *cydAB* genes [182]. The *cydABCD* operon coding for cytochrome *bd* in *B. subtilis* was reported to be activated by ResD and repressed by YdiH (Rex) and CcpA regulators [183–185]. Rex is also a repressor for the *cydABCD* operon in *Streptomyces coelicolor* [127]. ResD may activate the *cydA* gene in *L. monocytogenes* [105]. In *Rhodobacter capsulatus*, expression of cytochrome *bd* is likely controlled by RegA regulator [186].

5. Distribution and Evolution

The *bd*-family of oxygen reductases has a wide phylogenetic distribution with homologs found in at least one sequenced member of 18 bacterial phyla: Acidobacteria, Actinobacteria, Aquificae, Bacteroidetes, Chlamydiae, Caldithrix, Chlorobi, Chloroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Firmicutes, Nitrospirae, Planctomycetes, Proteobacteria, Thermi, Thermodesulfobacteria and Verrucomicrobia. To date no *bd*-family homologues have been detected in the following 12 bacterial phyla: Dictyoglomi, Elusimicrobia, Fibrobacteres, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Poribacteria, Synergistetes, Thermotogales, and candidate phyla NC10, TM7 and WWE1. A number of Archaea also encode *bd*-family homologues, with members of the family found in Crenarchaeota, Euryarchaeota [60] and Korarchaeota. Cytochrome *bd*-type oxygen reductases are very common in some phyla, such as the Proteobacteria and Actinobacteria,

and sporadically distributed in others. Interestingly, *bd*-family homologues have been detected in many species described as strict anaerobes such as *Methanosarcina barkeri*, *Methanosarcina acetivorans* [60], *Bacteroides fragilis* [86], *Desulfovibrio gigas* [187–189], *Desulfovibrio vulgaris* Hildenborough [190], *Geobacter metallireducens* [116], *Moorella thermoacetica* [191] and *Chlorobaculum tepidum* [192].

Early work suggested that the *bd*-family of oxygen reductases is an ancient innovation, already present in the ancestor of both Bacteria and Archaea [193]. However it was recently reported that the family may have originated in Bacteria and was later acquired by Archaea via horizontal gene transfer [60,194]. Phylogenetic analysis of the *bd*-family showed that horizontal gene transfer plays a significant role in the distribution of the family, with many phyla acquiring cytochrome *bd* genes multiple times independently (Fig. 3).

Sequence analysis has demonstrated that subunits I and II have different rates of evolution, with subunit II evolving 1.2 times faster than subunit I [194]. The biological relevance of this asymmetrical evolution is currently unknown.

6. Membrane localization

Cytochrome *bd* is embedded in the prokaryotic cytoplasmic (plasma) membrane. It was reported that in *E. coli*, cytochrome *bd*-I is not evenly distributed within the plasma membrane, being concentrated in mobile (on the subsecond time scale) patches, of the order of 100 nm in diameter [195,196]. These clusters contain variable numbers of cytochrome *bd*-I tetramers [196]. Cytochrome *bd* in cyanobacteria [197–203] has been reported to also be located in the thylakoid membrane [200,201,203–207], though this has been disputed [208–211]. The presence of a *bd*-type PQH₂ oxidase in cyanobacterial thylakoid and/or cytoplasmic membranes may depend on culturing conditions and the light regime [201,206].

7. Cofactors and Substrates

7.1. Quinones

The nature of the quinols used by cytochrome *bd* as an electron donor is species-specific. For instance, in *A. vinelandii* and *E. coli* the cytochrome *bd* enzyme can oxidize ubiquinol (UQH₂), in *B. stearothermophilus*, the substrate is menaquinol (MQH₂). In *E. coli*, cytochrome *bd*-I can also oxidize MQH₂ [212,213], which replaces UQH₂ upon change of growth conditions from aerobic to anaerobic [166]. There is evidence that in cyanobacteria cytochrome *bd* is active as a plastoquinol (PQH₂) oxidase [200,201,203–206], although some reports have questioned this conclusion [208–210]. The presence or absence of bound Q in solubilized cytochrome *bd*-I from *E. coli* depends on the purification protocol. In some preparations of the purified enzyme, there is no apparently bound quinone [26,27,46,214] whereas others clearly contain bound quinone [41,215]. A stable semiquinone radical has been observed in the *E. coli* cytochrome *bd*-I [216,217].

7.2. Hemes

The two subunits of *E. coli* cytochrome *bd*-I carry three metal-containing redox-centers, two protoheme IX groups (hemes *b*₅₅₈ and *b*₅₉₅) and a chlorin molecule (heme *d*) which are in 1:1:1 stoichiometry per the enzyme complex. The enzyme contains no Fe-S cluster and no copper ion [218–222]. Heme *b*₅₅₈ is clearly located within subunit I. Both subunits are required for the assembly of heme *b*₅₉₅ and heme *d*, suggesting that these two hemes may reside at the subunit interface [151]. Heme *b*₅₉₅ appears to be oriented with its heme plane at ~55° to the plane of the membrane [223]. The millimolar extinction coefficients used commonly for the determination of the cytochrome *bd* concentration in *E. coli* and *A. vinelandii* are listed in Table 2.

7.2.1. Heme b_{558} —Heme b_{558} has been shown to be located within subunit I by expressing subunit I (*cydA*) in the absence of subunit II (*cydB*) and showing that the isolated subunit I contains heme b_{558} [152]. Antibodies directed against subunit I [61,63], as well as selective proteolysis of this subunit [62,64], inhibit UQH₂ oxidase activity of cytochrome *bd*-I. These findings suggest that heme b_{558} is associated with subunit I and is involved in QH₂ oxidation. The α - and β -bands of the reduced heme b_{558} at room temperature reveal maxima at 560–562 and 531–532 nm, respectively (Table 3) [150,224,225]. The maximum and minimum of the γ -band in the “reduced *minus* oxidized” difference absorption spectrum are 429.5 and 413 nm, respectively (Table 3) [225]. Heme b_{558} is low-spin hexacoordinate [37], and amino acid residues His186** and Met393 of subunit I (*E. coli* cytochrome *bd*-I) have been identified as its axial ligands [226–228]. The location of heme b_{558} is predicted to be near the periplasmic surface [67,229].

7.2.2. Heme b_{595} —The spectrum of heme b_{595} is similar to that of catalases and peroxidases containing pentacoordinate (high-spin) protoheme IX [150]. Heme b_{595} has an α -band at 594–595 nm and β -band at 560–562 nm in the difference absorption spectrum (Table 3) [150,224,225]. A trough at 643–645 nm in the difference spectrum of heme b_{595} is indicative of the disappearance in the reduced heme b_{595} of an absorption feature due to charge transfer from the Fe to the ligand, characteristic of oxidized high-spin heme *b*, as in the case of peroxidases. The γ -band of ferrous heme b_{595} is characterized by a maximum at ~440 nm as clearly revealed by femtosecond spectroscopy [38]. The maximum and minimum of the γ -band in the difference “reduced *minus* oxidized” absorption spectrum are 439 and 400 nm, respectively (Table 3) [225]. Heme b_{595} is high-spin pentacoordinate [37], ligated by His19 of subunit I [230] and located near the periplasmic surface [67,229]. The role of heme b_{595} remains obscure. It is proposed that heme b_{595} participates in the reduction of O₂ forming, together with heme *d*, a di-heme O₂-reducing site, somewhat similar to the heme/Cu O₂-reducing site in heme-copper oxidases [35–41,43,231]. In favor of this hypothesis is the finding that the CD spectrum of the reduced wild type cytochrome *bd* in the Soret band shows strong excitonic interaction between ferrous hemes *d* and b_{595} [42]. Modeling the excitonic interactions in the absorption and CD spectra yields an estimate of the Fe-to-Fe distance between heme *d* and heme b_{595} to be about 10 Å [42]. In the opinion of some, the function of heme b_{595} is limited to transferring an electron from heme b_{558} to heme *d* [232,233], whereas others have postulated that heme b_{595} can form a second site capable of reacting with O₂ [218,234].

7.2.3. Heme *d*—Heme *d* is a chlorin-type molecule [235]. The α -band of the reduced heme *d* in the absolute absorption spectrum of *E. coli* cytochrome *bd*-I shows a peak at 628–630 nm. However, upon isolation of the enzyme, heme *d* is in the stable oxygenated (O₂-ligated ferrous) form, which is characterized by an absorption band with a maximum at 647–650 nm in the absolute absorption spectrum [236–239]. The affinity of ferrous heme *d* for O₂ is indeed high, showing the $K_{d(O_2)}$ values of 0.28 μ M and 0.5 μ M for the enzymes from *E. coli* and *A. vinelandii*, respectively [240,241]. The maximum and minimum of the γ -band in the difference “reduced *minus* oxidized” absorption spectrum are 430 and 405 nm, respectively (Table 3) [225].

Remarkably, the spectral contribution of heme *d* to the complex Soret band is much smaller than those of either hemes *b* [225]. Heme *d* is predicted to be located near the periplasmic surface [67,229], and is the site for capturing and, subsequently, reducing O₂ to H₂O. In the absence of external ligands, heme *d* is in the high-spin state with an open coordination site for binding O₂. The nature of the axial ligation of heme *d* to the protein, or even whether

** Here and below – amino acid numbering refers to cytochrome *bd*-I from *E. coli*

there is an axial ligand provided by the protein, is unclear. It has been claimed that the reduction of cytochrome *bd* is associated with binding of an endogenous protein ligand to heme *d* [242]. The oxidized heme *d* may or may not be ligated to an endogenous protein substituent. Resonance Raman and ENDOR studies indicate that the ligand is not histidine, cysteine or tyrosinate, but that the single axial ligand is either a weakly coordinating protein donor or a water molecule [230,243,244]. In contrast, EPR studies indicated that the heme *d* axial ligand is histidine in an anomalous condition or some other nitrogenous amino acid residue [245]. Finally, it has been suggested that Glu99 of subunit I is a prime candidate for such a role [214,246].

7.3. Heme redox potentials

The apparent values for the midpoint redox potentials of hemes *b*₅₅₈, *b*₅₉₅ and *d* for the *bd* enzymes solubilized in *n*-dodecyl- β -D-maltoside at pH 7.0 (E_m) are respectively +176, +168, +258 mV (*E. coli bd*-I) and +166, +251, +310 mV (*A. vinelandii*) [241]. These are within the range of the values reported earlier for *E. coli* [219,220,224,247,248] and *A. vinelandii* [249]. Notably, the E_m value of heme *b*₅₅₈ can depend on the detergent used for solubilization [248]. In particular, octylglucoside and cholate cause a large decrease in the E_m value of heme *b*₅₅₈, and this correlates with the reversible inactivation of the enzyme [248]. The E_m values of all three heme components of cytochrome *bd* are sensitive to pH between pH 5.8 and 8.3 with a E_m /pH of -61 mV for heme *d* and -40 mV for hemes *b*₅₅₈ and *b*₅₉₅, indicating that reduction of cytochrome *bd* is accompanied by enzyme protonation [248]. A recent study [225] revealed a significant redox interaction between heme *b*₅₅₈ and heme *b*₅₉₅, whereas the interaction between heme *d* and either both hemes *b* appears to be rather weak. However, the presence of heme *d* itself decreases the much larger interaction between the two hemes *b* [225].

8. Proposed structure

The X-ray structure of cytochrome *bd* has not been determined. Conventional studies of the protein topology in the membrane suggest that all three hemes are located near the periplasmic side of the membrane [67,229], although an alternative view also exists [250,251]. Fig. 4 shows topological models of subunits I (CydA) and II (CydB) of cytochrome *bd*-I from *E. coli* [213]. Both subunits are integral membrane proteins. Subunit I consists of nine transmembrane helices with the N-terminus in the periplasm and the C-terminus in the cytoplasm [67]. Subunit II is composed of eight transmembrane helices with both N- and C-termini in the cytoplasm [67]. The Q-loop in subunit I connects transmembrane helices 6 and 7, and is directly involved in QH₂ binding and oxidation [61–66]. Thus the QH₂-oxidizing site in cytochrome *bd* is located on the periplasmic side of the membrane. Cytochrome *bd*-I from *E. coli* is proposed to contain a single site for the binding and oxidation of quinol [65,66,252]. However, evidence for a second quinone binding site in cytochrome *bd* from *Corynebacterium glutamicum* has also reported [69].

Using a set of 815 sequences of genes encoding cytochrome *bd*, a number of residues in subunit I are totally (>99%) conserved [213]. These residues include those which are identified as ligands to the heme components of the enzyme. In addition, since the active site of O₂ reduction is located near the periplasmic surface and protons for H₂O production are taken from the bacterial cytoplasm, there must be at least one transmembrane proton-conducting pathway to convey protons from the cytoplasm to the heme *b*₅₉₅/heme *d* site [41,46,48,67] (Fig. 5). Several polar or ionizable residues that are highly conserved in the *bd*-family have been postulated to be a part of this putative proton channel.

The residues that are totally conserved within the entire *bd*-family include His19 (the heme *b*₅₉₅ axial ligand [230]), His186 and Met393 (the heme *b*₅₅₈ axial ligands [226–228]),

Lys252 and Glu257 (involved in QH₂ binding [66]), Arg448 (unknown function), and Glu99, Glu107, and Ser140 (proposed to be components of a proton channel [48,67] and important for heme binding in the heme *d*/heme *b*₅₉₅ di-heme site [213,214]). Slightly less conserved (95–99%) are Glu445 (required for charge compensation of the *b*₅₉₅/*d* O₂-reducing site upon its full reduction by two electrons [41]), Asn148 (plausible component of a proton channel), and Arg9 (unknown function) [213]. Somewhat less conserved (~85%) are Arg391 (stabilizes the reduced form of heme *b*₅₅₈ [253]) and Asp239 (unknown function), however these residues are totally conserved within the A subfamily of cytochromes *bd* [213]. Other conserved residues are glycines, prolines, phenylalanines, or tryptophans, which may play structural roles. There is only one totally (>99%) conserved residue (Trp57) in subunit II [213]. Within the subfamily of *bd*-type oxygen reductases which have the “long Q-loop”, Arg100, Asp29, and Asp120 of subunit II are totally conserved and Asp58 (subunit II of *E. coli* cytochrome *bd*-I) is either an aspartate or glutamate [213]. The N-terminal portion of subunit II has been suggested to be involved in the binding of heme *d*/heme *b*₅₉₅ [213,254].

Fig. 3 shows an unrooted tree showing the relative sequence relationships of 815 sequences of cytochrome *bd* from the genomes of Bacteria and Archaea. It is seen in Fig. 3 that the “long Q-loop” members form a phylogenetic clade distinct from the other members of the family. This is most likely due to an insertional event within the Q-loop. This subfamily contains many, but not all, of the cytochrome *bd* oxygen reductases from Proteobacteria (including *E. coli*). Also shown in Fig. 3 are two clades that define the *bd*-family members found in Archaea. In contrast, the *bd*-family oxygen reductases found in Firmicutes or Bacteroides are distributed widely among the phylogenetic groups shown in Fig. 3. This illustrates the large role played by horizontal gene transfer in the distribution of the *bd*-type oxygen reductases.

9. Binding of ligands (other than O₂)

Since hemes *d* and *b*₅₉₅ in cytochrome *bd* are in the high-spin pentacoordinate state, they could potentially bind ligands. One may anticipate that the enzyme in the reduced state binds electroneutral molecules like O₂, CO, and NO, whereas the oxidized cytochrome *bd* prefers ligands in the anionic form such as cyanide and azide. Heme *d* binds ligands readily whereas the ligand reactivity of heme *b*₅₉₅ is minor despite the fact that this is a high spin heme [37,39,255]. Heme *b*₅₅₈, although a low-spin hexacoordinate, may also bind ligands to some extent (e.g., CO or cyanide) [37,255]. Such a marginal reactivity is possibly due to weakening the bond of the methionine axial ligand (Met393) to heme *b*₅₅₈ iron caused by the isolation procedure and/or protein denaturation [255].

9.1. Carbon monoxide

Addition of CO to the three-electron reduced form of cytochrome *bd*, denoted as **R**³, causes a red shift of the 628 nm heme *d* band and the increased absorption around 540 nm in the visible, as well as a distinctive W-shaped difference spectrum in the Soret region [37,39,150,255–257]. The W-shaped feature is due to a small bandshift of unligated heme *b*₅₉₅ induced by CO interaction with the nearby heme *d* [38,40,43]. Only a small fraction of heme *b*₅₉₅ (<5%) in cytochrome *bd* binds CO at room or low temperature [37,39]. The apparent *K*_d for the CO-heme *d* complex with the fully reduced (**R**³) cytochrome *bd*-I from *E. coli* was determined to be ~80 nM [255]. The **R**³ cytochrome *bd* can form a photosensitive heme *d*-CO complex [258]. Flash photolysis of CO bound to heme *d* at cryogenic temperatures results in a redistribution of CO such that as much 15% of heme *b*₅₉₅ is bound to CO, showing the proximity of these two hemes [35]. Following flash-photolysis of the heme *d*-CO complex in the fully reduced enzyme (**R**³) at room temperature, CO recombines with ferrous heme *d* proportionally to the external CO

concentration with a second order bimolecular rate constant of $10^8 \text{ M}^{-1} \text{ s}^{-1}$ (Table 4) [43,222,249,259].

The one-electron reduced form of the enzyme (\mathbf{R}^1) can also be examined. Since heme *d* has a substantially higher midpoint potential than the other two heme components, heme *d* is the only heme reduced in the \mathbf{R}^1 , or mixed-valence, state of the ‘as prepared’ enzyme. Upon reaction with CO, one gets the CO-heme *d* adduct ($b_{558}^{3+}b_{595}^{3+}d^{2+}\text{-CO}$) [38,40,43,48,107,249]. After flash photolysis of the $\mathbf{R}^1\text{-CO}$ complex, a substantial fraction of the CO flashed off heme d^{2+} gets trapped inside the protein and undergoes geminate recombination with heme d^{2+} on the pico- and nanosecond time scale [38,43]. The data indicate that the redox state of heme b_{595} controls the pathway for ligand (CO) transfer between heme *d* and the bulk phase, which is open when heme b_{595} is reduced but closed when heme b_{595} is oxidized [38,43,107].

9.2. Nitric oxide and other nitrogen-containing ligands

A number of small nitrogen-containing molecules can react with \mathbf{R}^3 cytochrome *bd* from *E. coli* and *A. vinelandii*. NO_3^- , NO_2^- , $\text{N}_2\text{O}_3^{2-}$ (trioxodinitrate), NH_2OH and NO , when added to membranes containing cytochrome *bd* or the purified enzyme, give rise to decrease in amplitude and shift of the 630 nm peak of ferrous heme *d* to 641–645 nm [31,37,106,107,218,245,257,260–264]. It appears that all of these ligands result in chemical reactions, forming the same or a very similar heme-nitrosyl compound [31], e.g., heme $d^{2+}\text{-NO}$ adduct. It has also been suggested that a heme $b_{595}^{2+}\text{-NO}$ adduct can be observed upon adding nitrite to cytochrome *bd* in membranes [218].

Cytochrome *bd* can also produce a stable complex with NO in the \mathbf{R}^1 state, in which ligand bound heme *d* is reduced while the *b* hemes are oxidized [107,245]. The rates of NO dissociation from heme d^{2+} in both \mathbf{R}^3 and \mathbf{R}^1 states of cytochrome *bd* were determined [107]. In the \mathbf{R}^3 state, NO dissociates from heme d^{2+} at an unusually high rate, $k_{\text{off}} = 0.133 \text{ s}^{-1}$ [107], which is ~30-fold higher than the off-rate measured for the ferrous heme a_3 of the mitochondrial cytochrome *c* oxidase ($k_{\text{off}} = 0.004 \text{ s}^{-1}$ [265]). These data are consistent with the proposal that, in the heme–copper oxidases, Cu_B acts as a gate controlling ligand binding to the heme in the active site [266]. Another remarkable feature of NO dissociation from cytochrome *bd* is that the k_{off} value in the \mathbf{R}^1 state (0.036 s^{-1}), although still quite high, is significantly lower than that measured with the \mathbf{R}^3 enzyme [107] (Table 4). These data show that the redox state of heme b_{595} controls the kinetic barrier for ligand dissociation from the active site of cytochrome *bd*, similar to the observations with CO dissociation from ferrous heme *d* [38,43,107]. The unusually high NO dissociation rate from cytochrome *bd* may explain the observation [106] that the NO -poisoned cytochrome *bd* recovers respiratory function much more rapidly than a heme–copper oxygen reductase. It is postulated that expression of *bd*-type, instead of heme–copper-type oxygen reductase, enhances bacterial tolerance to nitrosative stress, thus promoting colonization of host intestine or other microaerobic environments [107,108]. It was reported that, apart from ferrous heme *d*, NO can also react with the oxoferryl and ferric state of heme *d*, yielding the oxidized nitrite-bound heme *d* and the nitrosyl adduct, respectively [110,111].

9.3. Cyanide

Reaction of ‘air-oxidized’ cytochrome *bd* with KCN causes the decay of the ferrous heme *d* oxy-complex [267–273]. Cyanide-induced changes to the EPR-spectrum include a low-spin signal and, after prolonged incubation, a second weak low-spin signal that may indicate some interaction of cyanide with heme b_{595} [220,257,274]. A simple and fast method for conversion of the oxygenated enzyme into the \mathbf{O} form with the use of lipophilic electron acceptors [239] allowed us to study the interaction of cyanide with the homogenous oxidized

preparation of cytochrome *bd* [37]. The MCD spectrum of the **O** cytochrome *bd*-I from *E. coli* is dominated by an asymmetric signal in the Soret. Submillimolar cyanide has no effect on the initial MCD spectrum. 50 mM KCN induces minor changes of the MCD signal in the Soret band, which can be modeled as transition of a part of the low-spin heme b_{558} (15–20%) to its low-spin cyano-complex [37]. There is no evidence of the interaction of high-spin ferric heme b_{595} with the ligand [37]. On the contrary, based on the EPR spectra, Tsubaki et al. [36] proposed that the treatment of ‘air-oxidized’ cytochrome *bd* with cyanide results in a cyanide-bridging species with a “heme d^{3+} –C=N–heme b_{595}^{3+} ” structure. However the authors [36] did not account for the electron released from heme *d* upon cyanide binding to ‘as prepared’ cytochrome *bd*. Resonance Raman studies suggest that heme *d* is in the high-spin pentacoordinate state when it is compounded with cyanide [230,275]. This would require either that the endogenous axial ligand to heme *d* is displaced by cyanide, maintaining a high-spin pentacoordinate state, or that there is no endogenous axial ligand to heme *d* in the fully oxidized form of the enzyme.

9.4. Hydrogen peroxide

Addition of excess H_2O_2 to *E. coli* membranes containing cytochrome *bd*-I [276] and the purified enzyme in the ‘as prepared’ [231,237] or the **O** [46,231,277] states gives rise to an absorption band at ~680 nm. The reaction of H_2O_2 with the **O** cytochrome *bd* also induces a red shift of the γ -band [231,277]. H_2O_2 binds to ferric heme *d* with an apparent K_d value of 30 μ M, but it seems not to interact with heme b_{595} [231,277]. The **O** cytochrome *bd* reacts with H_2O_2 with a second order rate constant of 600 $M^{-1} s^{-1}$. The decay of the H_2O_2 -induced spectral changes upon addition of catalase ($k \sim 10^{-3} s^{-1}$) is about 20-fold slower than expected for dissociation of H_2O_2 from the complex with heme *d* assuming a simple reversible binding of peroxide [277]. This suggests that the interaction of H_2O_2 with cytochrome *bd* is essentially irreversible, giving rise to the **F** state of heme *d* [277]. The assignment of the compound 680 to the **F** state of heme *d* is confirmed by resonance Raman spectroscopy data [221]. Heme *d* in the **F** state is suggested to be high-spin pentacoordinate [275].

10. Proposed catalytic mechanism

As discussed above, under physiological conditions cytochrome *bd* from different prokaryotes likely oxidizes UQH_2 , MQH_2 or PQH_2 . *In vitro* a *bd*-type oxygen reductase can also utilize short chain ubiquinols, menadiol, duroquinol, and artificial electron donors such as TMPD. Of the *in vitro* substrates, ubiquinol-1 (plus excess dithiothreitol) shows the highest turnover numbers [248,278]. The activity of the purified oxidase depends on the nature of the detergent in which the enzyme is solubilized. Cytochrome *bd*-I from *E. coli* is inactive in octylglucoside or cholate but shows high activity in Tween-20, Triton X-100 [248] or *N*-lauroyl-sarcosine [106]. The ubiquinol-1 oxidase activity of cytochrome *bd*-I has a broad optimum above pH 7.5 but decreases at more acidic pH values [248]. Cytochrome *bd* possesses three distinct active sites - for QH_2 oxidation, TMPD oxidation and O_2 reduction. All the three sites seem to be located at or close to the periplasmic surface of the membrane. Electrons donated from QH_2 transfer to heme b_{558} and then to the b_{595}/d di-heme site, whereas electrons donated from TMPD transfer directly to the b_{595}/d site bypassing the QH_2 -binding site and heme b_{558} [62,279].

10.1. Mechanism of generation of the proton motive force

Cytochrome *bd* from *E. coli* and *A. vinelandii* was reported to generate a transmembrane electric potential both in single turnover [41,46–48] and under multiple turnover [27,44,280] conditions ($H^+/e^- \sim 1$ [34,45,49,50]; $q/e^- \sim 1$ [281]). When reconstituted into liposomes, cytochrome *bd* generates an uncoupler-sensitive transmembrane voltage difference with a

value of 160–180 mV (negative inside) [27,44]. The QH₂ molecule generated by the dehydrogenases of the respiratory chain can diffuse laterally within the bilayer, finding its way into the QH₂ oxidizing site located near the outer side of the membrane. Upon oxidation of QH₂, two protons are released into the periplasmic space, and two electrons are transferred through heme *b*₅₅₈ to the *b*₅₉₅/*d* O₂-reducing site, also located near the periplasmic surface of the membrane. The four protons used for O₂ reduction are taken up from the cytoplasm. Single-turnover electrometric experiments show that the generation of the membrane potential is associated with electron transfer from heme *b*₅₅₈ to the *b*₅₉₅/*d* active site [41,46–48]. However, since all of the three hemes are likely located close to the periplasmic side of the membrane [67,229], the electron transfer itself is expected to be parallel to the membrane surface and, therefore, cannot be electrogenic [46]. Rather, it is proposed that electron transfer from heme *b*₅₅₈ to the *b*₅₉₅/*d* active site is coupled to vectorial proton transfer from the cytoplasm towards the active site on the opposite (periplasmic) side of the membrane [41,46–48]. The latter implies that there must be a proton-conducting channel connecting the cytoplasm to the *b*₅₉₅/*d* active site [41,46,48] (Fig. 5). The transmembrane potential originates primarily from protons moving from the cytoplasm to the O₂-reducing site on the opposite side of the membrane, and this accompanies electron transfer from heme *b*₅₅₈ to the *b*₅₉₅/*d* active site. As shown in Fig. 5, it is proposed that near the *b*₅₉₅/*d* active site there are two protonatable sites (X_P and X_N) that are accessible to the cytoplasm *via* a proton-conducting channel.

10.2. Reaction of the fully reduced enzyme (R³) with O₂

The reaction of the R³ cytochrome *bd* with O₂ has been studied using the flow-flash method [282] by means of spectroscopic and electrometric techniques [41,46–48,222]. Recording absorption spectra and membrane potential development with 1 μs time resolution resolves the sequence of the catalytic intermediates and establishes which catalytic steps are linked to electric potential generation [47]. The scheme for this reaction is presented in Fig. 6 (**top panel**). The initial complex of R³ cytochrome *bd* with CO (R³-CO) is photolyzed (the photolysis details are shown in Fig. 6, **bottom panel**) in the presence of O₂. The unliganded R³ enzyme, generated by the CO-photolysis, binds O₂ very rapidly, forming the ferrous heme *d* oxy species (A³). The R³→A³ transition is not electrogenic and its rate is proportional to [O₂] ($k_{on} = 1.9 \times 10^9 \text{ M}^{-1}\cdot\text{s}^{-1}$ [47,222]). The A³ formation is followed by electron transfer from heme *b*₅₉₅ to form state P. The A³→P transition occurs with $\tau = 4.5 \mu\text{s}$ and is also nonelectrogenic [47]. Thus, electron transfer from heme *b*₅₉₅ to heme *d* is not coupled to membrane potential generation [41,47]. It is proposed that P is a peroxy complex of ferric heme *d* [47]. If this is the case, the bound peroxide is likely not to be in the anionic form but at least singly protonated. The proton may come from one of two postulated protonatable groups, X_P and X_N, near the *b*₅₉₅/*d* di-heme active site upon oxidation of the hemes [41]. P is further converted into F upon electron transfer from heme *b*₅₅₈ with $\tau = 48 \mu\text{s}$. Formation of F is coupled to generation of a membrane potential [41,46–48] due to the accompanying proton transfer through the proposed proton channel (Fig. 5). At the F stage, the *b*-type hemes are in a ferric state and heme *d* in an oxoferryl state. When cytochrome *bd* contains bound QH₂, the reaction proceeds further to form the O enzyme. The F→O transition occurs with $\tau = 1.1 \text{ ms}$ and is electrogenic as well [41,47] since this also involves electron transfer from heme *b*₅₅₈ to the *b*₅₉₅/*d* active site with the accompanying proton transfer.

Cytochrome *bd* can bind O₂ being in the R¹ state. Remarkably, in this reaction, the dependence of the rate of O₂ binding on [O₂] is hyperbolic thus revealing a saturation behavior. This is not observed for O₂ binding to the R³ enzyme [241]. It is speculated that the R¹ enzyme exists in the two different conformations in equilibrium, but only one of these forms binds to O₂. When in the “closed” conformation, cytochrome *bd* provides no

access for O₂ to heme d^{2+} , whereas in the “open” conformation, O₂ binds easily. The **R³** enzyme is always in the open conformation [241].

10.3. Catalytic cycle

Several relatively stable forms of cytochrome *bd* corresponding to the intermediates of the catalytic cycle have been identified. Under aerobic conditions, cytochrome *bd* is predominantly in the one-electron-reduced state bound to O₂ (**A¹**), with lesser amounts of the **F** and **O** forms. Under anaerobic conditions, the reduced forms of the enzyme lacking an O₂ ligand with one (**R¹**) and three (**R³**) electrons can be generated and examined. A short-lived complex of the three-electron reduced cytochrome *bd* with O₂ (**A³**) [46,47,222,241], an “peroxide” intermediate **P** [47] and an oxoferryl compound **F** [46,47,222] can be sequentially formed (Fig. 6). Turnover intermediates of *E. coli* cytochrome *bd*-I detected at steady-state are **A¹** and **F** species (~40% each) and, to a lesser extent (~20%), a species with ferric heme *d* and possibly one electron on heme *b*₅₅₈ (**R¹**) [283]. These data differ from those obtained with mammalian cytochrome *c* oxidase, in which oxygenous intermediates were not found to be populated at detectable levels under similar conditions [284]. A plausible scheme of the catalytic cycle of cytochrome *bd* is shown in Fig. 7.

10.4. Role of heme *b*₅₉₅

Exogenous ligands added to cytochrome *bd* bind to heme *d* but do not bind to a majority of the heme *b*₅₉₅ population [31,37,39,255]. Heme *b*₅₉₅, although in the high-spin pentacoordinate state, is resistant to interaction with the classical ligands of high-spin iron-porphyrin complexes. It cannot be ruled out that despite the high-spin pentacoordinate state of the iron-porphyrin group, the specific features of the protein environment are such that this redox cofactor is protected from interaction with ligands. In such case, the participation of heme *b*₅₉₅ in O₂ reduction in cooperation with heme *d* is unlikely and its role would be limited to the transfer of an electron to heme *d*. A more likely explanation is the following: (1) both heme *b*₅₉₅ and heme *d* potentially can bind ligands; (2) the hemes are located close to each other forming a di-heme active site; (3) the spatial proximity of hemes *b*₅₉₅ and *d* results in steric restrictions allowing the di-heme site to bind only one ligand molecule; (4) heme *d* has a higher affinity for ligands than heme *b*₅₉₅, in which case the final result observed upon addition of a ligand will always be the ligand binding to heme *d*, whereas heme *b*₅₉₅ will remain mainly in the unliganded state [37,39,231,255]. The data on the redox coupling of the two hemes to the same ionizable groups [41], and the migration of CO within the protein from heme *d* to heme *b*₅₉₅ at cryogenic temperatures [35] are in agreement with this proposal. Modeling the excitonic interactions in absorption and CD spectra of cytochrome *bd* yields an estimate of the Fe_{*d*}-to-Fe_{*b*₅₉₅} distance of about 10 Å [42]. This is markedly larger than that for the Fe/Cu_B pair in heme-copper oxidases (4–5 Å). If this is the case, heme *b*₅₉₅ cannot be a functional analogue of Cu_B. A possible role of heme *b*₅₉₅, apart from electron delivery to heme *d* and/or to an oxygenated intermediate form of heme *d*, would be as a binding site for hydroxide produced from heme *d*-bound O₂ upon reductive cleavage of the O-O bond [42].

11. Conclusion

There are at least two reasons why cytochromes *bd* may be of interest. First, they are found in many pathogenic bacteria and there is growing evidence for a positive correlation between the virulence and the level of cytochrome *bd* expression. We hope that our knowledge on the structure and function of the *bd* enzymes will provide new tools to combat diseases caused by pathogens, for instance, by using a bacterial *bd*-type respiratory oxygen reductases as a drug target. Second, it would be useful to know what are the common features and the differences between the mechanisms of O₂ reduction to H₂O by

cytochromes *bd* and heme-copper oxidases. Such a comparison could allow us to gain further insight into the elements essential for proton pumping coupled to the redox reaction inherent in heme-copper oxidases.

Acknowledgments

Studies in our groups were supported by the Russian Foundation for Basic Research, grant 11-04-00031-a (to V.B.B.), the National Institutes of Health, grant HL16101 (to R.B.G.), and the Biocentrum Helsinki, the Sigrid Jusélius Foundation, the Academy of Finland (to M.I.V.).

Abbreviations

AOX	alternative oxidase
CIO	cyanide-insensitive quinol oxidase
E_m	apparent midpoint redox potential
IC₅₀	the half maximal inhibitory concentration
PMF	proton motive force
TMPD	<i>N,N,N',N'</i> -tetramethyl- <i>p</i> -phenyldiamine
Q	quinone
QH₂	quinol
UQH₂	ubiquinol
MQH₂	menaquinol
PQH₂	plastoquinol
A¹	one electron-reduced O ₂ -bound species
A³	fully reduced O ₂ -bound species
R¹	one electron-reduced species
R³	fully reduced species
O	fully oxidized species
F	oxoferryl species
P	peroxide-bound species
$\Delta\mu_{H^+}$	transmembrane difference in the electrochemical H ⁺ potentials
τ	time constant reciprocal of rate constant ($t_{1/e}$)

References

1. Brunori M, Giuffrè A, Sarti P. Cytochrome *c* oxidase, ligands and electrons. *J Inorg Biochem.* 2005; 99:324–336. [PubMed: 15598510]
2. Hosler JP, Ferguson-Miller S, Mills DA. Energy transduction: proton transfer through the respiratory complexes. *Annu Rev Biochem.* 2006; 75:165–187. [PubMed: 16756489]
3. Branden G, Gennis RB, Brzezinski P. Transmembrane proton translocation by cytochrome *c* oxidase. *Biochim Biophys Acta.* 2006; 1757:1052–1063. [PubMed: 16824482]
4. Wikström M, Verkhovskiy MI. Mechanism and energetics of proton translocation by the respiratory heme-copper oxidases. *Biochim Biophys Acta.* 2007; 1767:1200–1214. [PubMed: 17689487]
5. Belevich I, Verkhovskiy MI. Molecular mechanism of proton translocation by cytochrome *c* oxidase. *Antioxid Redox Signal.* 2008; 10:1–29. [PubMed: 17949262]

6. Richter OM, Ludwig B. Electron transfer and energy transduction in the terminal part of the respiratory chain - Lessons from bacterial model systems. *Biochim Biophys Acta*. 2009; 1787:626–634. [PubMed: 19268423]
7. Brzezinski P, Johansson AL. Variable proton-pumping stoichiometry in structural variants of cytochrome *c* oxidase. *Biochim Biophys Acta*. 2010; 1797:710–723. [PubMed: 20184858]
8. Pereira MM, Santana M, Teixeira M. A novel scenario for the evolution of haem-copper oxygen reductases. *Biochim Biophys Acta*. 2001; 1505:185–208. [PubMed: 11334784]
9. Pereira MM, Sousa FL, Verissimo AF, Teixeira M. Looking for the minimum common denominator in haem-copper oxygen reductases: towards a unified catalytic mechanism. *Biochim Biophys Acta*. 2008; 1777:929–934. [PubMed: 18515066]
10. Chang HY, Hemp J, Chen Y, Fee JA, Gennis RB. The cytochrome *ba₃* oxygen reductase from *Thermus thermophilus* uses a single input channel for proton delivery to the active site and for proton pumping. *Proc Natl Acad Sci USA*. 2009; 106:16169–16173. [PubMed: 19805275]
11. Buschmann S, Warkentin E, Xie H, Langer JD, Ermler U, Michel H. The structure of *cbb₃* cytochrome oxidase provides insights into proton pumping. *Science*. 2010; 329:327–330. [PubMed: 20576851]
12. Hemp J, Han H, Roh JH, Kaplan S, Martinez TJ, Gennis RB. Comparative genomics and site-directed mutagenesis support the existence of only one input channel for protons in the C-family (*cbb₃* oxidase) of heme-copper oxygen reductases. *Biochemistry*. 2007; 46:9963–9972. [PubMed: 17676874]
13. Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, Shinzawa-Itoh K, Nakashima T, Yaono R, Yoshikawa S. Structures of metal sites of oxidized bovine heart cytochrome *c* oxidase at 2.8 Å. *Science*. 1995; 269:1069–1074. [PubMed: 7652554]
14. Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, Shinzawa-Itoh K, Nakashima R, Yaono R, Yoshikawa S. The whole structure of the 13-subunit oxidized cytochrome *c* oxidase at 2.8 Å. *Science*. 1996; 272:1136–1144. [PubMed: 8638158]
15. Yoshikawa S, Shinzawa-Itoh K, Nakashima R, Yaono R, Yamashita E, Inoue N, Yao M, Fei MJ, Libeu CP, Mizushima T, Yamaguchi H, Tomizaki T, Tsukihara T. Redox-coupled crystal structural changes in bovine heart cytochrome *c* oxidase. *Science*. 1998; 280:1723–1729. [PubMed: 9624044]
16. Iwata S, Ostermeier C, Ludwig B, Michel H. Structure at 2.8 Å resolution of cytochrome *c* oxidase from *Paracoccus denitrificans*. *Nature*. 1995; 376:660–669. [PubMed: 7651515]
17. Abramson J, Svensson-Ek M, Byrne B, Iwata S. Structure of cytochrome *c* oxidase: a comparison of the bacterial and mitochondrial enzymes. *Biochim Biophys Acta*. 2001; 1544:1–9. [PubMed: 11341911]
18. Svensson-Ek M, Abramson J, Larsson G, Tornroth S, Brzezinski P, Iwata S. The X-ray crystal structures of wild-type and EQ(I-286) mutant cytochrome *c* oxidases from *Rhodobacter sphaeroides*. *J Mol Biol*. 2002; 321:329–339. [PubMed: 12144789]
19. Soulimane T, Buse G, Bourenkov GP, Bartunik HD, Huber R, Than ME. Structure and mechanism of the aberrant *ba₃*-cytochrome *c* oxidase from *Thermus thermophilus*. *EMBO J*. 2000; 19:1766–1776. [PubMed: 10775261]
20. Abramson J, Riistama S, Larsson G, Jasaitis A, Svensson-Ek M, Laakkonen L, Puustinen A, Iwata S, Wikstrom M. The structure of the ubiquinol oxidase from *Escherichia coli* and its ubiquinone binding site. *Nat Struct Biol*. 2000; 7:910–917. [PubMed: 11017202]
21. Ostermeier C, Harrenga A, Ermler U, Michel H. Structure at 2.7 Å resolution of the *Paracoccus denitrificans* two-subunit cytochrome *c* oxidase complexed with an antibody Fv fragment. *Proc Natl Acad Sci USA*. 1997; 94:10547–10553. [PubMed: 9380672]
22. Qin L, Hiser C, Mulichak A, Garavito RM, Ferguson-Miller S. Identification of conserved lipid/detergent-binding sites in a high-resolution structure of the membrane protein cytochrome *c* oxidase. *Proc Natl Acad Sci USA*. 2006; 103:16117–16122. [PubMed: 17050688]
23. Koepke J, Olkhova E, Angerer H, Muller H, Peng G, Michel H. High resolution crystal structure of *Paracoccus denitrificans* cytochrome *c* oxidase: new insights into the active site and the proton transfer pathways. *Biochim Biophys Acta*. 2009; 1787:635–645. [PubMed: 19374884]

24. Albury MS, Elliott C, Moore AL. Towards a structural elucidation of the alternative oxidase in plants. *Physiol Plant*. 2009; 137:316–327. [PubMed: 19719482]
25. Kido Y, Shiba T, Inaoka DK, Sakamoto K, Nara T, Aoki T, Honma T, Tanaka A, Inoue M, Matsuoka S, Moore A, Harada S, Kita K. Crystallization and preliminary crystallographic analysis of cyanide-insensitive alternative oxidase from *Trypanosoma brucei brucei*. *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2010; 66:275–278.
26. Miller MJ, Gennis RB. The purification and characterization of the cytochrome *d* terminal oxidase complex of the *Escherichia coli* aerobic respiratory chain. *J Biol Chem*. 1983; 258:9159–9165. [PubMed: 6307994]
27. Kita K, Konishi K, Anraku Y. Terminal oxidases of *Escherichia coli* aerobic respiratory chain. II. Purification and properties of cytochrome *b_{558-d}* complex from cells grown with limited oxygen and evidence of branched electron-carrying systems. *J Biol Chem*. 1984; 259:3375–3381. [PubMed: 6321507]
28. Green GN, Fang H, Lin R-J, Newton G, Mather M, Georgiou CD, Gennis RB. The nucleotide sequence of the *cyd* locus encoding the two subunits of the cytochrome *d* terminal oxidase complex of *Escherichia coli*. *J Biol Chem*. 1988; 263:13138–13143. [PubMed: 2843510]
29. Poole RK. Oxygen reactions with bacterial oxidases and globins: binding, reduction and regulation. *Anthonie van Leeuwenhoek*. 1994; 65:289–310.
30. Trumppower BL, Gennis RB. Energy transduction by cytochrome complexes in mitochondrial and bacterial respiration: The enzymology of coupling electron transfer reactions to transmembrane proton translocation. *Annu Rev Biochem*. 1994; 63:675–716. [PubMed: 7979252]
31. Junemann S. Cytochrome *bd* terminal oxidase. *Biochim Biophys Acta*. 1997; 1321:107–127. [PubMed: 9332500]
32. Borisov VB. Cytochrome *bd*: structure and properties. *Biochemistry (Moscow)*. 1996; 61:565–574. (translated from *Biokhimiya* (in Russian) (1996), 61, 786–799).
33. Tsubaki M, Hori H, Mogi T. Probing molecular structure of dioxygen reduction site of bacterial quinol oxidases through ligand binding to the redox metal centers. *J Inorg Biochem*. 2000; 82:19–25. [PubMed: 11132627]
34. Miller MJ, Hermodson M, Gennis RB. The active form of the cytochrome *d* terminal oxidase complex of *Escherichia coli* is a heterodimer containing one copy of each of the two subunits. *J Biol Chem*. 1988; 263:5235–5240. [PubMed: 3281937]
35. Hill JJ, Alben JO, Gennis RB. Spectroscopic evidence for a heme-heme binuclear center in the cytochrome *bd* ubiquinol oxidase from *Escherichia coli*. *Proc Natl Acad Sci USA*. 1993; 90:5863–5867. [PubMed: 8516338]
36. Tsubaki M, Hori H, Mogi T, Anraku Y. Cyanide-binding site of *bd*-type ubiquinol oxidase from *Escherichia coli*. *J Biol Chem*. 1995; 270:28565–28569. [PubMed: 7499371]
37. Borisov V, Arutyunyan AM, Osborne JP, Gennis RB, Konstantinov AA. Magnetic circular dichroism used to examine the interaction of *Escherichia coli* cytochrome *bd* with ligands. *Biochemistry*. 1999; 38:740–750. [PubMed: 9888814]
38. Vos MH, Borisov VB, Liebl U, Martin J-L, Konstantinov AA. Femtosecond resolution of ligand-heme interactions in the high-affinity quinol oxidase *bd*: A di-heme active site? *Proc Natl Acad Sci USA*. 2000; 97:1554–1559. [PubMed: 10660685]
39. Borisov VB, Sedelnikova SE, Poole RK, Konstantinov AA. Interaction of cytochrome *bd* with carbon monoxide at low and room temperatures: evidence that only a small fraction of heme *b₅₉₅* reacts with CO. *J Biol Chem*. 2001; 276:22095–22099. [PubMed: 11283005]
40. Borisov VB, Liebl U, Rappaport F, Martin J-L, Zhang J, Gennis RB, Konstantinov AA, Vos MH. Interactions between heme *d* and heme *b₅₉₅* in quinol oxidase *bd* from *Escherichia coli*: a photoselection study using femtosecond spectroscopy. *Biochemistry*. 2002; 41:1654–1662. [PubMed: 11814360]
41. Belevich I, Borisov VB, Zhang J, Yang K, Konstantinov AA, Gennis RB, Verkhovsky MI. Time-resolved electrometric and optical studies on cytochrome *bd* suggest a mechanism of electron-proton coupling in the di-heme active site. *Proc Natl Acad Sci USA*. 2005; 102:3657–3662. [PubMed: 15728392]

42. Arutyunyan AM, Borisov VB, Novoderezhkin VI, Ghaim J, Zhang J, Gennis RB, Konstantinov AA. Strong excitonic interactions in the oxygen-reducing site of *bd*-type oxidase: the Fe-to-Fe distance between hemes *d* and *b₅₉₅* is 10 Å. *Biochemistry*. 2008; 47:1752–1759. [PubMed: 18205406]
43. Rappaport F, Zhang J, Vos MH, Gennis RB, Borisov VB. Heme-heme and heme-ligand interactions in the di-heme oxygen-reducing site of cytochrome *bd* from *Escherichia coli* revealed by nanosecond absorption spectroscopy. *Biochim Biophys Acta*. 2010; 1797:1657–1664. [PubMed: 20529691]
44. Miller MJ, Gennis RB. The cytochrome *d* complex is a coupling site in the aerobic respiratory chain of *Escherichia coli*. *J Biol Chem*. 1985; 260:14003–14008. [PubMed: 2414286]
45. Puustinen A, Finel M, Haltia T, Gennis RB, Wikstrom M. Properties of the two terminal oxidases of *Escherichia coli*. *Biochemistry*. 1991; 30:3936–3942. [PubMed: 1850294]
46. Jasaitis A, Borisov VB, Belevich NP, Morgan JE, Konstantinov AA, Verkhovskiy MI. Electrogenic reactions of cytochrome *bd*. *Biochemistry*. 2000; 39:13800–13809. [PubMed: 11076519]
47. Belevich I, Borisov VB, Verkhovskiy MI. Discovery of the true peroxy intermediate in the catalytic cycle of terminal oxidases by real-time measurement. *J Biol Chem*. 2007; 282:28514–28519. [PubMed: 17690093]
48. Borisov VB, Belevich I, Bloch DA, Mogi T, Verkhovskiy MI. Glutamate 107 in subunit I of cytochrome *bd* from *Escherichia coli* is part of a transmembrane intraprotein pathway conducting protons from the cytoplasm to the heme *b₅₉₅*/heme *d* active site. *Biochemistry*. 2008; 47:7907–7914. [PubMed: 18597483]
49. Kolonay JF Jr, Maier RJ. Formation of pH and potential gradients by the reconstituted *Azotobacter vinelandii* cytochrome *bd* respiratory protection oxidase. *J Bacteriol*. 1997; 179:3813–3817. [PubMed: 9171438]
50. Bertsova YV, Bogachev AV, Skulachev VP. Generation of protonic potential by the *bd*-type quinol oxidase of *Azotobacter vinelandii*. *FEBS Lett*. 1997; 414:369–372. [PubMed: 9315721]
51. Ingledew WJ, Poole RK. The respiratory chains of *Escherichia coli*. *Microbiol Rev*. 1984; 48:222–271. [PubMed: 6387427]
52. Poole RK, Cook GM. Redundancy of aerobic respiratory chains in bacteria? Routes, reasons and regulation. *Adv Microb Physiol*. 2000; 43:165–224. [PubMed: 10907557]
53. Borisov, VB.; Verkhovskiy, MI. *EcoSal - Escherichia coli and Salmonella: cellular and molecular biology*. Bock, A.; RCI; Kaper, JB.; Karp, PD.; Neidhardt, FC.; Nystrom, T.; Slauch, JM.; Squires, CL.; Ussery, D., editors. ASM Press; Washington, DC: 2009. <http://www.ecosal.org>
54. Trutko SM, Evtushenko LI, Dorofeeva LV, Shlyapnikov MG, Gavrish EY, Suzina NE, Akimenko VK. Terminal oxidases in representatives of different genera of the family *Microbacteriaceae*. *Microbiology (Moscow)*. 2003; 72:301–307.
55. Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. The complete genome sequence of *Escherichia coli* K-12. *Science*. 1997; 277:1453–1462. [PubMed: 9278503]
56. Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al. The complete genome sequence of the gram-positive bacterium *Bacillus subtilis*. *Nature*. 1997; 390:249–256. [PubMed: 9384377]
57. Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM. DNA sequence of both chromosomes of the cholera pathogen *Vibrio cholerae*. *Nature*. 2000; 406:477–483. [PubMed: 10952301]
58. Brooijmans RJ, de Vos WM, Hugenholtz J. *Lactobacillus plantarum* WCFS1 electron transport chains. *Appl Environ Microbiol*. 2009; 75:3580–3585. [PubMed: 19346351]

59. Sootsuwan K, Lertwattanasakul N, Thanonkeo P, Matsushita K, Yamada M. Analysis of the respiratory chain in Ethanologenic *Zymomonas mobilis* with a cyanide-resistant *bd*-type ubiquinol oxidase as the only terminal oxidase and its possible physiological roles. *J Mol Microbiol Biotechnol.* 2008; 14:163–175. [PubMed: 18089934]
60. Brochier-Armanet C, Talla E, Gribaldo S. The multiple evolutionary histories of dioxygen reductases: Implications for the origin and evolution of aerobic respiration. *Mol Biol Evol.* 2009; 26:285–297. [PubMed: 18974088]
61. Kranz RG, Gennis RB. Characterization of the cytochrome *d* terminal oxidase complex of *Escherichia coli* using polyclonal and monoclonal antibodies. *J Biol Chem.* 1984; 259:7998–8003. [PubMed: 6376498]
62. Lorence RM, Carter K, Gennis RB, Matsushita K, Kaback HR. Trypsin proteolysis of the cytochrome *d* complex of *Escherichia coli* selectively inhibits ubiquinol oxidase activity while not affecting *N,N,N',N'*-tetramethyl-*p*-phenylenediamine oxidase activity. *J Biol Chem.* 1988; 11:5271–5276. [PubMed: 2833503]
63. Dueweke TJ, Gennis RB. Epitopes of monoclonal antibodies which inhibit ubiquinol oxidase activity of *Escherichia coli* cytochrome *d* complex localize a functional domain. *J Biol Chem.* 1990; 265:4273–4277. [PubMed: 1689724]
64. Dueweke TJ, Gennis RB. Proteolysis of the cytochrome *d* complex with trypsin and chymotrypsin localizes a quinol oxidase domain. *Biochemistry.* 1991; 30:3401–3406. [PubMed: 1707310]
65. Matsumoto Y, Murai M, Fujita D, Sakamoto K, Miyoshi H, Yoshida M, Mogi T. Mass spectrometric analysis of the ubiquinol-binding site in cytochrome *bd* from *Escherichia coli*. *J Biol Chem.* 2006; 281:1905–1912. [PubMed: 16299377]
66. Mogi T, Akimoto S, Endou S, Watanabe-Nakayama T, Mizuochi-Asai E, Miyoshi H. Probing the ubiquinol-binding site in cytochrome *bd* by site-directed mutagenesis. *Biochemistry.* 2006; 45:7924–7930. [PubMed: 16784245]
67. Osborne JP, Gennis RB. Sequence analysis of cytochrome *bd* oxidase suggests a revised topology for subunits I. *Biochim Biophys Acta.* 1999; 1410:32–50. [PubMed: 10076013]
68. Sakamoto J, Koga E, Mizuta T, Sato C, Noguchi S, Sone N. Gene structure and quinol oxidase activity of a cytochrome *bd*-type oxidase from *Bacillus stearothermophilus*. *Biochim Biophys Acta.* 1999; 1411:147–158. [PubMed: 10216161]
69. Kusumoto K, Sakiyama M, Sakamoto J, Noguchi S, Sone N. Menaquinol oxidase activity and primary structure of cytochrome *bd* from the amino-acid fermenting bacterium *Corynebacterium glutamicum*. *Arch Microbiol.* 2000; 173:390–397. [PubMed: 10896219]
70. Azarkina N, Siletsky S, Borisov V, von Wachenfeldt C, Hederstedt L, Konstantinov AA. A cytochrome *bb'*-type quinol oxidase in *Bacillus subtilis* strain 168. *J Biol Chem.* 1999; 274:32810–32817. [PubMed: 10551842]
71. Cunningham L, Williams HD. Isolation and characterization of mutants defective in the cyanide-insensitive respiratory pathway of *Pseudomonas aeruginosa*. *J Bacteriol.* 1995; 177:432–438. [PubMed: 7814333]
72. Zannoni D. The respiratory chains of pathogenic pseudomonads. *Biochim Biophys Acta.* 1989; 975:299–316. [PubMed: 2667644]
73. Cunningham L, Pitt M, Williams HD. The *cioAB* genes from *Pseudomonas aeruginosa* code for a novel cyanide-insensitive terminal oxidase related to the cytochrome *bd* quinol oxidases. *Mol Microbiol.* 1997; 24:579–591. [PubMed: 9179851]
74. Quesada A, Guijo MI, Merchan F, Blazquez B, Igeno MI, Blasco R. Essential role of cytochrome *bd*-related oxidase in cyanide resistance of *Pseudomonas pseudoalcaligenes* CECT5344. *Appl Environ Microbiol.* 2007; 73:5118–5124. [PubMed: 17574992]
75. Jackson RJ, Elvers KT, Lee LJ, Gidley MD, Wainwright LM, Lightfoot J, Park SF, Poole RK. Oxygen reactivity of both respiratory oxidases in *Campylobacter jejuni*: the *cydAB* genes encode a cyanide-resistant, low-affinity oxidase that is not of the cytochrome *bd* type. *J Bacteriol.* 2007; 189:1604–1615. [PubMed: 17172349]
76. Matsushita K, Yamada M, Shinagawa E, Adachi O, Ameyama M. Membrane-bound respiratory chain of *Pseudomonas aeruginosa* grown aerobically. A KCN-insensitive alternate oxidase chain and its energetics. *J Biochem.* 1983; 93:1137–1144. [PubMed: 6305927]

77. Morales G, Ugidos A, Rojo F. Inactivation of the *Pseudomonas putida* cytochrome *o* ubiquinol oxidase leads to a significant change in the transcriptome and to increased expression of the CIO and *cbb3*-1 terminal oxidases. *Environ Microbiol.* 2006; 8:1764–1774. [PubMed: 16958757]
78. Voggu L, Schlag S, Biswas R, Rosenstein R, Rausch C, Gotz F. Microevolution of cytochrome *bd* oxidase in Staphylococci and its implication in resistance to respiratory toxins released by *Pseudomonas*. *J Bacteriol.* 2006; 188:8079–8086. [PubMed: 17108291]
79. Mogi T, Ano Y, Nakatsuka T, Toyama H, Muroi A, Miyoshi H, Migita CT, Ui H, Shiomi K, Omura S, Kita K, Matsushita K. Biochemical and spectroscopic properties of cyanide-insensitive quinol oxidase from *Gluconobacter oxydans*. *J Biochem.* 2009; 146:263–271. [PubMed: 19416958]
80. Mogi T, Miyoshi H. Properties of cytochrome *bd* plastoquinol oxidase from the cyanobacterium *Synechocystis* sp. PCC 6803. *J Biochem.* 2009; 145:395–401. [PubMed: 19124292]
81. Blumer C, Haas D. Mechanism, regulation, and ecological role of bacterial cyanide biosynthesis. *Arch Microbiol.* 2000; 173:170–177. [PubMed: 10763748]
82. Castric PA. Hydrogen cyanide production by *Pseudomonas aeruginosa* at reduced oxygen levels. *Can J Microbiol.* 1983; 29:1344–1349. [PubMed: 6318940]
83. Goldfarb WB, Margraf H. Cyanide production by *Pseudomonas aeruginosa*. *Ann Surg.* 1967; 165:104–110. [PubMed: 4959845]
84. Zlosnik JEA, Tavankar GR, Bundy JG, Mossialos D, O'Toole R, Williams HD. Investigation of the physiological relationship between the cyanide-insensitive oxidase and cyanide production in *Pseudomonas aeruginosa*. *Microbiology.* 2006; 152:1407–1415. [PubMed: 16622057]
85. Tavankar GR, Mossialos D, Williams HD. Mutation or overexpression of a terminal oxidase leads to a cell division defect and multiple antibiotic sensitivity in *Pseudomonas aeruginosa*. *J Biol Chem.* 2003; 278:4524–4530. [PubMed: 12435732]
86. Baughn AD, Malamy MH. The strict anaerobe *Bacteroides fragilis* grows in and benefits from nanomolar concentrations of oxygen. *Nature.* 2004; 427:441–444. [PubMed: 14749831]
87. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. Changes in energy metabolism of *Mycobacterium tuberculosis* in mouse lung and under in vitro conditions affecting aerobic respiration. *Proc Natl Acad Sci USA.* 2005; 102:15629–15634. [PubMed: 16227431]
88. Loisel-Meyer S, Jimenez de Bagues MP, Kohler S, Liautard JP, Jubier-Maurin V. Differential use of the two high-oxygen-affinity terminal oxidases of *Brucella suis* for in vitro and intramacrophagic multiplication. *Infect Immun.* 2005; 73:7768–7771. [PubMed: 16239582]
89. Jones SA, Chowdhury FZ, Fabich AJ, Anderson A, Schreiner DM, House AL, Autieri SM, Leatham MP, Lins JJ, Jorgensen M, Cohen PS, Conway T. Respiration of *Escherichia coli* in the mouse intestine. *Infect Immun.* 2007; 75:4891–4899. [PubMed: 17698572]
90. Kelly MJS, Poole RK, Yates MG, Kennedy C. Cloning and mutagenesis of genes encoding the cytochrome *bd* terminal oxidase complex in *Azotobacter vinelandii*: Mutants deficient in the cytochrome *d* complex are unable to fix nitrogen in air. *J Bacteriol.* 1990; 172:6010–6019. [PubMed: 2170336]
91. Hill S, Viollet S, Smith AT, Anthony C. Roles for enteric *d*-type cytochrome oxidase in N₂ fixation and microaerobiosis. *J Bacteriol.* 1990; 172:2071–2078. [PubMed: 2156809]
92. Smith A, Hill S, Anthony C. The purification, characterization and role of the *d*-type cytochrome oxidase of *Klebsiella pneumoniae* during nitrogen fixation. *J Gen Microbiol.* 1990; 136:171–180. [PubMed: 2191076]
93. D'Mello R, Hill S, Poole RK. Determination of the oxygen affinities of terminal oxidases in *Azotobacter vinelandii* using the deoxygenation of oxyleghaemoglobin and oxymyoglobin: Cytochrome *bd* is a low-affinity oxidase. *Microbiology.* 1994; 140:1395–1402.
94. Kaminski PA, Kitts CL, Zimmerman Z, Ludwig RA. *Azorhizobium caulinodans* uses both cytochrome *bd* (quinol) and cytochrome *cbb3* (cytochrome *c*) terminal oxidases for symbiotic N₂ fixation. *J Bacteriol.* 1996; 178:5989–5994. [PubMed: 8830696]
95. Juty NS, Moshiri F, Merrick M, Anthony C, Hill S. The *Klebsiella pneumoniae* cytochrome *bd*' terminal oxidase complex and its role in microaerobic nitrogen fixation. *Microbiology.* 1997; 143:2673–2683. [PubMed: 9274021]

96. Poole RK, Hill S. Respiratory protection of nitrogenase activity in *Azotobacter vinelandii* - roles of the terminal oxidases. *Bioscience Reports*. 1997; 17:307–317.
97. Bertsova YV, Demin OV, Bogachev AV. Respiratory protection of nitrogenase complex in *Azotobacter vinelandii*. *Uspekhi biologicheskoy khimii* (in Russian). 2005; 45:205–234.
98. Dincturk HB, Demir V, Aykanat T. *Bd* oxidase homologue of photosynthetic purple sulfur bacterium *Allochromatium vinosum* is co-transcribed with a nitrogen fixation related gene. *Antonie van Leeuwenhoek*. 2011; 99:211–220. [PubMed: 20577808]
99. Hassani BK, Steunou AS, Liotenberg S, Reiss-Husson F, Astier C, Ouchane S. Adaptation to oxygen: role of terminal oxidases in photosynthesis initiation in the purple photosynthetic bacterium, *Rubrivivax gelatinosus*. *J Biol Chem*. 2010; 285:19891–19899. [PubMed: 20335164]
100. Way SS, Sallustio S, Magliozzo RS, Goldberg MB. Impact of either elevated or decreased levels of cytochrome *bd* expression on *Shigella flexneri* virulence. *J Bacteriol*. 1999; 181:1229–1237. [PubMed: 9973350]
101. Endley S, McMurray D, Ficht TA. Interruption of the *cydB* locus in *Brucella abortus* attenuates intracellular survival and virulence in the mouse model of infection. *J Bacteriol*. 2001; 183:2454–2462. [PubMed: 11274104]
102. Yamamoto Y, Poyart C, Trieu-Cuot P, Lamberet G, Gruss A, Gaudu P. Respiration metabolism of Group B Streptococcus is activated by environmental haem and quinone and contributes to virulence. *Mol Microbiol*. 2005; 56:525–534. [PubMed: 15813741]
103. Zhang-Barber L, Turner AK, Martin G, Frankel G, Dougan G, Barrow PA. Influence of genes encoding proton-translocating enzymes on suppression of *Salmonella typhimurium* growth and colonization. *J Bacteriol*. 1997; 179:7186–7190. [PubMed: 9371470]
104. Turner AK, Barber LZ, Wigley P, Muhammad S, Jones MA, Lovell MA, Hulme S, Barrow PA. Contribution of proton-translocating proteins to the virulence of *Salmonella enterica* Serovars Typhimurium, Gallinarum, and Dublin in chickens and mice. *Infect Immun*. 2003; 71:3392–3401. [PubMed: 12761123]
105. Larsen MH, Kallipolitis BH, Christiansen JK, Olsen JE, Ingmer H. The response regulator ResD modulates virulence gene expression in response to carbohydrates in *Listeria monocytogenes*. *Mol Microbiol*. 2006; 61:1622–1635. [PubMed: 16968229]
106. Borisov VB, Forte E, Konstantinov AA, Poole RK, Sarti P, Giuffre A. Interaction of the bacterial terminal oxidase cytochrome *bd* with nitric oxide. *FEBS Lett*. 2004; 576:201–204. [PubMed: 15474037]
107. Borisov VB, Forte E, Sarti P, Brunori M, Konstantinov AA, Giuffre A. Redox control of fast ligand dissociation from *Escherichia coli* cytochrome *bd*. *Biochem Biophys Res Commun*. 2007; 355:97–102. [PubMed: 17280642]
108. Mason MG, Shepherd M, Nicholls P, Dobbin PS, Dodsworth KS, Poole RK, Cooper CE. Cytochrome *bd* confers nitric oxide resistance to *Escherichia coli*. *Nat Chem Biol*. 2009; 5:94–96. [PubMed: 19109594]
109. Forte E, Borisov VB, Konstantinov AA, Brunori M, Giuffre A, Sarti P. Cytochrome *bd*, a key oxidase in bacterial survival and tolerance to nitrosative stress. *Ital J Biochem*. 2007; 56:265–269. [PubMed: 19192624]
110. Borisov VB, Forte E, Sarti P, Brunori M, Konstantinov AA, Giuffre A. Nitric oxide reacts with the ferryl-oxo catalytic intermediate of the Cu_B-lacking cytochrome *bd* terminal oxidase. *FEBS Lett*. 2006; 580:4823–4826. [PubMed: 16904110]
111. Borisov VB, Forte E, Giuffre A, Konstantinov A, Sarti P. Reaction of nitric oxide with the oxidized di-heme and heme-copper oxygen-reducing centers of terminal oxidases: Different reaction pathways and end-products. *J Inorg Biochem*. 2009; 103:1185–1187. [PubMed: 19592112]
112. Lindqvist A, Membrillo-Hernandez J, Poole RK, Cook GM. Roles of respiratory oxidases in protecting *Escherichia coli* K12 from oxidative stress. *Antonie Van Leeuwenhoek*. 2000; 78:23–31. [PubMed: 11016692]
113. Borisov VB, Davletshin AI, Konstantinov AA. Peroxidase activity of cytochrome *bd* from *Escherichia coli*. *Biochemistry (Moscow)*. 2010; 75:428–436. (translated from *Biokhimiya* (in Russian) (2010), 75, 520–530). [PubMed: 20618131]

114. Korshunov S, Imlay JA. Two sources of endogenous hydrogen peroxide in *Escherichia coli*. *Mol Microbiol.* 2010; 75:1389–1401. [PubMed: 20149100]
115. Huycke MM, Moore D, Joyce W, Wise P, Shepard L, Kotake Y, Gilmore MS. Extracellular superoxide production by *Enterococcus faecalis* requires demethylmenaquinone and is attenuated by functional terminal quinol oxidases. *Mol Microbiol.* 2001; 42:729–740. [PubMed: 11722738]
116. Heintz D, Gallien S, Wischgoll S, Ullmann AK, Schaeffer C, Kretzschmar AK, van Dorsselaer A, Boll M. Differential membrane proteome analysis reveals novel proteins involved in the degradation of aromatic compounds in *Geobacter metallireducens*. *Mol Cell Proteomics.* 2009; 8:2159–2169. [PubMed: 19497847]
117. Edwards SE, Loder CS, Wu G, Corker H, Bainbridge BW, Hill S, Poole RK. Mutation of cytochrome *bd* quinol oxidase results in reduced stationary phase survival, iron deprivation, metal toxicity and oxidative stress in *Azotobacter vinelandii*. *FEMS Microbiol Lett.* 2000; 185:71–77. [PubMed: 10731609]
118. Bader M, Muse W, Ballou DP, Gassner C, Bardwell JCA. Oxidative protein folding is driven by the electron transport system. *Cell.* 1999; 98:217–227. [PubMed: 10428033]
119. Mobius K, Arias-Cartin R, Breckau D, Hannig AL, Riedmann K, Biedendieck R, Schroder S, Becher D, Magalon A, Moser J, Jahn M, Jahn D. Heme biosynthesis is coupled to electron transport chains for energy generation. *Proc Natl Acad Sci USA.* 2010; 107:10436–10441. [PubMed: 20484676]
120. Rice CW, Hempfling WP. Oxygen-limited continuous culture and respiratory energy conservation in *Escherichia coli*. *J Bacteriol.* 1978; 134:115–124. [PubMed: 25879]
121. Cotter PA, Chepuri V, Gennis RB, Gunsalus RP. Cytochrome *o* (*cyoABCDE*) and *d* (*cydAB*) oxidase gene expression in *Escherichia coli* is regulated by oxygen, pH, and the *fnr* gene product. *J Bacteriol.* 1990; 172:6333–6338. [PubMed: 2172211]
122. Fu H-A, Iuchi S, Lin ECC. The requirement of ArcA and Fnr for peak expression of the *cyd* operon in *Escherichia coli* under microaerobic conditions. *Mol Gen Genet.* 1991; 226:209–213. [PubMed: 1851949]
123. Avetisyan AV, Bogachev AV, Murtasina RA, Skulachev VP. Involvement of a *d*-type oxidase in the Na⁺-motive respiratory chain of *Escherichia coli* growing under low $\Delta\mu_{\text{H}^+}$ conditions. *FEBS Lett.* 1992; 306:199–202. [PubMed: 1321735]
124. Wall D, Delaney JM, Fayet O, Lipinska B, Yamamoto T, Georgopoulos C. *arc*-Dependent thermal regulation and extragenic suppression of the *Escherichia coli* cytochrome *d* operon. *J Bacteriol.* 1992; 174:6554–6562. [PubMed: 1328158]
125. Delaney JM, Wall D, Georgopoulos C. Molecular characterization of the *Escherichia coli* *htrD* gene: Cloning, sequence, regulation, and involvement with cytochrome *d* oxidase. *J Bacteriol.* 1993; 175:166–175. [PubMed: 8380150]
126. Ashcroft JR, Haddock BA. Synthesis of alternative membrane-bound redox carriers during aerobic growth of *Escherichia coli* in the presence of potassium cyanide. *Biochem J.* 1975; 148:349–352. [PubMed: 1098659]
127. Brekasis D, Paget MS. A novel sensor of NADH/NAD⁺ redox poise in *Streptomyces coelicolor* A3(2). *EMBO J.* 2003; 22:4856–4865. [PubMed: 12970197]
128. Bogachev AV, Murtazina RA, Skulachev VP. Cytochrome *d* induction in *Escherichia coli* growing under unfavorable conditions. *FEBS Lett.* 1993; 336:75–78. [PubMed: 8262220]
129. Bogachev AV, Murtazine RA, Shestopalov AI, Skulachev VP. Induction of the *Escherichia coli* cytochrome *d* by low $\Delta\mu_{\text{H}^+}$ and by sodium ions. *Eur J Biochem.* 1995; 232:304–308. [PubMed: 7556165]
130. Tamegai H, Kato C, Horikoshi K. Pressure-regulated respiratory system in barotolerant bacterium, *Shewanella* sp. strain DSS12. *J Biochem Mol Biol Biophys.* 1998; 1:213–220.
131. Tamegai H, Kawano H, Ishii A, Chikuma S, Nakasone K, Kato C. Pressure-regulated biosynthesis of cytochrome *bd* in piezo- and psychrophilic deep-sea bacterium *Shewanella violacea* DSS12. *Extremophiles.* 2005; 9:247–253. [PubMed: 15844013]
132. Poole RK, Williams HD, Downie JA, Gibson F. Mutations affecting the cytochrome *d*-containing oxidase complex of *Escherichia coli* K12: Identification and mapping of a fourth locus, *cydD*. *J Gen Microbiol.* 1989; 135:1865–1874. [PubMed: 2559153]

133. Macinga DR, Rather PN. *aarD*, a *Providencia stuartii* homologue of *cydD*: role in 2'-N-acetyltransferase expression, cell morphology and growth in the presence of an extracellular factor. *Mol Microbiol.* 1996; 19:511–520. [PubMed: 8830242]
134. Cook GM, Loder C, Soballe B, Stafford GP, Membrillo-Hernandez J, Poole RK. A factor produced by *Escherichia coli* K-12 inhibits the growth of *E. coli* mutants defective in the cytochrome *bd* quinol oxidase complex: enterochelin rediscovered. *Microbiology.* 1998; 144:3297–3308. [PubMed: 9884221]
135. Siegele DA, Kolter R. Isolation and characterization of an *Escherichia coli* mutant defective in resuming growth after starvation. *Genes Dev.* 1993; 7:2629–2640. [PubMed: 8276245]
136. Siegele DA, Imlay KR, Imlay JA. The stationary-phase-exit defect of *cydC* (*surB*) mutants is due to the lack of a functional terminal cytochrome oxidase. *J Bacteriol.* 1996; 178:6091–6096. [PubMed: 8892804]
137. Mogi T, Ui H, Shiomi K, Omura S, Miyoshi H, Kita K. Antibiotics LL-Z1272 identified as novel inhibitors discriminating bacterial and mitochondrial quinol oxidases. *Biochim Biophys Acta.* 2009; 1787:129–133. [PubMed: 19111521]
138. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. *Cell Mol Life Sci.* 2009; 66:3821–3826. [PubMed: 19701717]
139. Borisov VB. Defects in mitochondrial respiratory complexes III, IV, and human pathologies. *Mol Aspects Med.* 2002; 23:385–412. [PubMed: 12231008]
140. Borisov VB. Mutations in respiratory chain complexes and human diseases. *Ital J Biochem.* 2004; 53:34–40. [PubMed: 15356960]
141. Gavrikova EV, Grivennikova VG, Borisov VB, Cecchini G, Vinogradov AD. Assembly of a chimeric respiratory chain from bovine heart submitochondrial particles and cytochrome *bd* terminal oxidase of *Escherichia coli*. *FEBS Lett.* 2009; 583:1287–1291. [PubMed: 19303413]
142. Perales-Clemente E, Bayona-Bafaluy MP, Perez-Martos A, Barrientos A, Fernandez-Silva P, Enriquez JA. Restoration of electron transport without proton pumping in mammalian mitochondria. *Proc Natl Acad Sci USA.* 2008; 105:18735–18739. [PubMed: 19020091]
143. Dassa EP, Dufour E, Goncalves S, Paupe V, Hakkaart GA, Jacobs HT, Rustin P. Expression of the alternative oxidase complements cytochrome *c* oxidase deficiency in human cells. *EMBO Mol Med.* 2009; 1:30–36. [PubMed: 20049701]
144. Dassa EP, Dufour E, Goncalves S, Jacobs HT, Rustin P. The alternative oxidase, a tool for compensating cytochrome *c* oxidase deficiency in human cells. *Physiol Plant.* 2009; 137:427–434. [PubMed: 19493305]
145. Mogi T, Ui H, Shiomi K, Omura S, Kita K. Gramicidin S identified as a potent inhibitor for cytochrome *bd*-type quinol oxidase. *FEBS Lett.* 2008; 582:2299–2302. [PubMed: 18519036]
146. Calhoun MW, Newton G, Gennis RB. *E. coli* map. Physical map locations of genes encoding components of the aerobic respiratory chain of *Escherichia coli*. *J Bacteriol.* 1991; 173:1569–1570. [PubMed: 1847904]
147. Kranz RG, Barassi CA, Miller MJ, Green GN, Gennis RB. Immunological characterization of an *E. coli* strain which is lacking cytochrome *d*. *J Bacteriol.* 1983; 156:115–121. [PubMed: 6311794]
148. Bachmann BJ. Linkage map of *Escherichia coli* K-12, Edition 8. *Microbiol Rev.* 1990; 54:130–197. [PubMed: 2194094]
149. Green GN, Kranz JE, Gennis RB. Cloning the *cyd* gene locus coding for the cytochrome *d* complex of *Escherichia coli*. *Gene.* 1984; 32:99–106. [PubMed: 6099317]
150. Lorence RM, Koland JG, Gennis RB. Coulometric and spectroscopic analysis of the purified cytochrome *d* complex of *Escherichia coli*: Evidence for the identification of “cytochrome *a*₁” as cytochrome *b*₅₉₅. *Biochemistry.* 1986; 25:2314–2321. [PubMed: 3013299]
151. Newton G, Gennis RB. In vivo assembly of the cytochrome *d* terminal oxidase complex of *Escherichia coli* from genes encoding the two subunits expressed on separate plasmids. *Biochim Biophys Acta.* 1991; 1089:8–12. [PubMed: 1851043]
152. Green GN, Lorence RM, Gennis RB. Specific overproduction and purification of the cytochrome *b*₅₅₈ component of the cytochrome *d* complex from *Escherichia coli*. *Biochemistry.* 1986; 25:2309–2314. [PubMed: 3013298]

153. Georgiou CD, Fang H, Gennis RB. Identification of the *cydC* locus required for the expression of the functional form of the cytochrome *d* terminal oxidase complex in *Escherichia coli*. *J Bacteriol.* 1987; 169:2107–2112. [PubMed: 3032907]
154. Poole RK, Hatch L, Cleeter MWJ, Gibson F, Cox GB, Wu G. Cytochrome *bd* biosynthesis in *Escherichia coli*: The sequences of the *cydC* and *cydD* genes suggest that they encode the components of an ABC membrane transporter. *Mol Microbiol.* 1993; 10:421–430. [PubMed: 7934832]
155. Bebbington KJ, Williams HD. Investigation of the role of the *cydD* gene product in production of a functional cytochrome *d* oxidase in *Escherichia coli*. *FEMS Microbiol Lett.* 1993; 112:19–24. [PubMed: 8405944]
156. Poole RK, Gibson F, Wu G. The *cydD* gene product, component of a heterodimeric ABC transporter, is required for assembly of periplasmic cytochrome *c* and of cytochrome *bd* in *Escherichia coli*. *FEMS Microbiol Lett.* 1994; 117:217–224. [PubMed: 8181727]
157. Pittman MS, Robinson HC, Poole RK. A bacterial glutathione transporter (*Escherichia coli* CydDC) exports reductant to the periplasm. *J Biol Chem.* 2005; 280:32254–32261. [PubMed: 16040611]
158. Stenberg F, Chovanec P, Maslen SL, Robinson CV, Ilag LL, von Heijne G, Daley DO. Protein complexes of the *Escherichia coli* cell envelope. *J Biol Chem.* 2005; 280:34409–34419. [PubMed: 16079137]
159. Mogi T, Mizuochi-Asai E, Endou S, Akimoto S, Nakamura H. Role of a putative third subunit YhcB on the assembly and function of cytochrome *bd*-type ubiquinol oxidase from *Escherichia coli*. *Biochim Biophys Acta.* 2006; 1757:860–864. [PubMed: 16863643]
160. Dassa J, Fsihi H, Marck C, Dion M, Kieffer-Bontemps M, Boquet PL. A new oxygen-regulated operon in *Escherichia coli* comprises the genes for a putative third cytochrome oxidase and for pH 2.5 acid phosphatase (*appA*). *Mol Gen Genet.* 1991; 229:341–352. [PubMed: 1658595]
161. Tseng C-P, Albrecht J, Gunsalus RP. Effect of microaerophilic cell growth conditions on expression of the aerobic (*cyoABCDE* and *cydAB*) and anaerobic (*narGHJI*, *frdABCD*, and *dmsABC*) respiratory pathway genes in *Escherichia coli*. *J Bacteriol.* 1996; 178:1094–1098. [PubMed: 8576043]
162. Alexeeva S, Hellingwerf K, Teixeira de Mattos MJ. Quantitative assessment of oxygen availability: Perceived aerobiosis and its effect on flux distribution in the respiratory chain of *Escherichia coli*. *J Bacteriol.* 2002; 184:1402–1406. [PubMed: 11844770]
163. Iuchi S, Chepuri V, Fu HA, Gennis RB, Lin EC. Requirement for terminal cytochromes in generation of the aerobic signal for the *arc* regulatory system in *Escherichia coli*: Study utilizing deletions and *lac* fusions of *cyo* and *cyd*. *J Bacteriol.* 1990; 172:6020–6025. [PubMed: 2170337]
164. Cotter PA, Gunsalus RP. Contribution of the *fir* and *arcA* gene products in coordinate regulation of cytochrome *o* and *d* oxidase (*cyoABCDE* and *cydAB*) genes in *Escherichia coli*. *FEMS Microbiol Lett.* 1992; 91:31–36. [PubMed: 1315704]
165. Gunsalus RP. Control of electron flow in *Escherichia coli*: Coordinated transcription of respiratory pathway genes. *J Bacteriol.* 1992; 174:7069–7074. [PubMed: 1331024]
166. Uden G, Bongaerts J. Alternative respiratory pathways of *Escherichia coli*: energetics and transcriptional regulation in response to electron acceptors. *Biochim Biophys Acta.* 1997; 1320:217–234. [PubMed: 9230919]
167. Cotter PA, Melville SB, Albrecht JA, Gunsalus RP. Aerobic regulation of cytochrome *d* oxidase (*cydAB*) operon expression in *Escherichia coli*: roles of Fnr and ArcA in repression and activation. *Mol Microbiol.* 1997; 25:605–615. [PubMed: 9302022]
168. Govantes F, Albrecht JA, Gunsalus RP. Oxygen regulation of the *Escherichia coli* cytochrome *d* oxidase (*cydAB*) operon: roles of multiple promoters and the Fnr-1 and Fnr-2 binding sites. *Mol Microbiol.* 2000; 37:1456–1469. [PubMed: 10998176]
169. Shalel-Levanon S, San KY, Bennett GN. Effect of oxygen, and ArcA and FNR regulators on the expression of genes related to the electron transfer chain and the TCA cycle in *Escherichia coli*. *Metabolic Engineering.* 2005; 7:364–374. [PubMed: 16140031]
170. Lynch, AS.; Lin, ECC. *Escherichia coli* and *Salmonella typhimurium*: Cellular and Molecular Biology. 2. Neidhardt, F, editor. ASM Press; Washington, D.C: 1996. p. 1526-1538.

171. Georgellis D, Kwon O, Lin EC. Quinones as the redox signal for the arc two-component system of bacteria. *Science*. 2001; 292:2314–2316. [PubMed: 11423658]
172. Georgellis D, Kwon O, Lin EC. Amplification of signaling activity of the arc two-component system of *Escherichia coli* by anaerobic metabolites. An in vitro study with different protein modules. *J Biol Chem*. 1999; 274:35950–35954. [PubMed: 10585483]
173. Alexeeva S, Hellingwerf KJ, Teixeira de Mattos MJ. Requirement of ArcA for redox regulation in *Escherichia coli* under microaerobic but not anaerobic or aerobic conditions. *J Bacteriol*. 2003; 185:204–209. [PubMed: 12486057]
174. Kiley PJ, Beinert H. Oxygen sensing by the global regulator, FNR: the role of the iron-sulfur cluster. *FEMS Microbiol Rev*. 1998; 22:341–352. [PubMed: 9990723]
175. Overton TW, Griffiths L, Patel MD, Hobman JL, Penn CW, Cole JA, Constantinidou C. Microarray analysis of gene regulation by oxygen, nitrate, nitrite, FNR, NarL and NarP during anaerobic growth of *Escherichia coli*: new insights into microbial physiology. *Biochem Soc Trans*. 2006; 34:104–107. [PubMed: 16417494]
176. Becker S, Holighaus G, Gabrielczyk T, Uden G. O₂ as the regulatory signal for FNR-dependent gene regulation in *Escherichia coli*. *J Bacteriol*. 1996; 178:4515–4521. [PubMed: 8755879]
177. Atlung T, Brondsted L. Role of the transcriptional activator AppY in regulation of the *cyx appA* operon of *Escherichia coli* by anaerobiosis, phosphate starvation, and growth phase. *J Bacteriol*. 1994; 176:5414–5422. [PubMed: 8071219]
178. Brondsted L, Atlung T. Effect of growth conditions on expression of the acid phosphatase (*cyx-appA*) operon and the *appY* gene, which encodes a transcriptional activator of *Escherichia coli*. *J Bacteriol*. 1996; 178:1556–1564. [PubMed: 8626281]
179. Sturr MG, Krulwich TA, Hicks DB. Purification of a cytochrome *bd* terminal oxidase encoded by the *Escherichia coli app* locus from a $\Delta cyo \Delta cyd$ strain complemented by genes from *Bacillus firmus* OF4. *J Bacteriol*. 1996; 176:1742–1749. [PubMed: 8626304]
180. Bekker M, de Vries S, Ter Beek A, Hellingwerf KJ, de Mattos MJ. Respiration of *Escherichia coli* can be fully uncoupled via the nonelectrogenic terminal cytochrome *bd*-II oxidase. *J Bacteriol*. 2009; 191:5510–5517. [PubMed: 19542282]
181. Shepherd M, Sanguinetti G, Cook GM, Poole RK. Compensations for diminished terminal oxidase activity in *Escherichia coli*: cytochrome *bd*-II-mediated respiration and glutamate metabolism. *J Biol Chem*. 2010; 285:18464–18472. [PubMed: 20392690]
182. Wu G, Cruz-Ramos H, Hill S, Green J, Sawers G, Poole RK. Regulation of cytochrome *bd* expression in the obligate aerobe *Azotobacter vinelandii* by CydR (Fnr). Sensitivity to oxygen, reactive oxygen species, and nitric oxide. *J Biol Chem*. 2000; 275:4679–4686. [PubMed: 10671497]
183. Schau M, Chen Y, Hulett FM. *Bacillus subtilis* YdiH is a direct negative regulator of the *cydABCD* operon. *J Bacteriol*. 2004; 186:4585–4595. [PubMed: 15231791]
184. Larsson JT, Rogstam A, von Wachenfeldt C. Coordinated patterns of cytochrome *bd* and lactate dehydrogenase expression in *Bacillus subtilis*. *Microbiology*. 2005; 151:3323–3335. [PubMed: 16207915]
185. Puri-Taneja A, Schau M, Chen Y, Hulett FM. Regulators of the *Bacillus subtilis cydABCD* operon: identification of a negative regulator, CcpA, and a positive regulator, ResD. *J Bacteriol*. 2007; 189:3348–3358. [PubMed: 17322317]
186. Swem LR, Elsen S, Bird TH, Swem DL, Koch HG, Myllykallio H, Daldal F, Bauer CE. The RegB/RegA two-component regulatory system controls synthesis of photosynthesis and respiratory electron transfer components in *Rhodobacter capsulatus*. *J Mol Biol*. 2001; 309:121–138. [PubMed: 11491283]
187. Lemos RS, Gomes CM, Santana M, LeGall J, Xavier AV, Teixeira M. The ‘strict’ anaerobe *Desulfovibrio gigas* contains a membrane-bound oxygen-reducing respiratory chain. *FEBS Lett*. 2001; 496:40–43. [PubMed: 11343703]
188. Lemos RS, Gomes CM, LeGall J, Xavier AV, Teixeira M. The quinol:fumarate oxidoreductase from the sulphate reducing bacterium *Desulfovibrio gigas*: spectroscopic and redox studies. *J Bioenerg Biomembr*. 2002; 34:21–30. [PubMed: 11860177]

189. Machado P, Felix R, Rodrigues R, Oliveira S, Rodrigues-Pousada C. Characterization and expression analysis of the cytochrome *bd* oxidase operon from *Desulfovibrio gigas*. *Curr Microbiol.* 2006; 52:274–281. [PubMed: 16550467]
190. Santana M. Presence and expression of terminal oxygen reductases in strictly anaerobic sulfate-reducing bacteria isolated from salt-marsh sediments. *Anaerobe.* 2008; 14:145–156. [PubMed: 18457966]
191. Das A, Silaghi-Dumitrescu R, Ljungdahl LG, Kurtz DM Jr. Cytochrome *bd* oxidase, oxidative stress, and dioxygen tolerance of the strictly anaerobic bacterium *Moorella thermoacetica*. *J Bacteriol.* 2005; 187:2020–2029. [PubMed: 15743950]
192. Li H, Jubelirer S, Garcia Costas AM, Frigaard NU, Bryant DA. Multiple antioxidant proteins protect *Chlorobaculum tepidum* against oxygen and reactive oxygen species. *Arch Microbiol.* 2009; 191:853–867. [PubMed: 19784828]
193. Castresana J. Comparative genomics and bioenergetics. *Biochim Biophys Acta.* 2001; 1506:147–162. [PubMed: 11779548]
194. Hao W, Golding GB. Asymmetrical evolution of cytochrome *bd* subunits. *J Mol Evol.* 2006; 62:132–142. [PubMed: 16474982]
195. Lenn T, Leake MC, Mullineaux CW. Clustering and dynamics of cytochrome *bd*-I complexes in the *Escherichia coli* plasma membrane *in vivo*. *Mol Microbiol.* 2008; 70:1397–1407. [PubMed: 19019148]
196. Lenn T, Leake MC, Mullineaux CW. Are *Escherichia coli* OXPHOS complexes concentrated in specialized zones within the plasma membrane? *Biochem Soc Trans.* 2008; 36:1032–1036. [PubMed: 18793184]
197. Kaneko T, Sato S, Kotani H, Tanaka A, Asamizu E, Nakamura Y, Miyajima N, Hirose M, Sugiura M, Sasamoto S, Kimura T, Hosouchi T, Matsuno A, Muraki A, Nakazaki N, Naruo K, Okumura S, Shimpo S, Takeuchi C, Wada T, Watanabe A, Yamada M, Yasuda M, Tabata S. Sequence analysis of the genome of the unicellular cyanobacterium *Synechocystis* sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. *DNA Res.* 1996; 3:109–136. [PubMed: 8905231]
198. Howitt CA, Vermaas WF. Quinol and cytochrome oxidases in the cyanobacterium *Synechocystis* sp. PCC 6803. *Biochemistry.* 1998; 37:17944–17951. [PubMed: 9922162]
199. Schneider D, Berry S, Rich P, Seidler A, Rogner M. A regulatory role of the PetM subunit in a cyanobacterial cytochrome *b₆f* complex. *J Biol Chem.* 2001; 276:16780–16785. [PubMed: 11278512]
200. Pils D, Schmetterer G. Characterization of three bioenergetically active respiratory terminal oxidases in the cyanobacterium *Synechocystis* sp. strain PCC 6803. *FEMS Microbiol Lett.* 2001; 203:217–222. [PubMed: 11583851]
201. Berry S, Schneider D, Vermaas WF, Rogner M. Electron transport routes in whole cells of *Synechocystis* sp. strain PCC 6803: the role of the cytochrome *bd*-type oxidase. *Biochemistry.* 2002; 41:3422–3429. [PubMed: 11876651]
202. Pils D, Wilken C, Valladares A, Flores E, Schmetterer G. Respiratory terminal oxidases in the facultative chemoheterotrophic and dinitrogen fixing cyanobacterium *Anabaena variabilis* strain ATCC 29413: characterization of the *cox2* locus. *Biochim Biophys Acta.* 2004; 1659:32–45. [PubMed: 15511525]
203. Schultze M, Forberich B, Rexroth S, Dyczmons NG, Roegner M, Appel J. Localization of cytochrome *b₆f* complexes implies an incomplete respiratory chain in cytoplasmic membranes of the cyanobacterium *Synechocystis* sp. PCC 6803. *Biochim Biophys Acta.* 2009; 1787:1479–1485. [PubMed: 19577535]
204. Berry S, Bolychevtseva YV, Rogner M, Karapetyan NV. Photosynthetic and respiratory electron transport in the alkaliphilic cyanobacterium *Arthrospira (Spirulina) platensis*. *Photosynth Res.* 2003; 78:67–76. [PubMed: 16245065]
205. Kufryk GI, Vermaas WF. Sll1717 affects the redox state of the plastoquinone pool by modulating quinol oxidase activity in thylakoids. *J Bacteriol.* 2006; 188:1286–1294. [PubMed: 16452410]

206. Gutthann F, Egert M, Marques A, Appel J. Inhibition of respiration and nitrate assimilation enhances photohydrogen evolution under low oxygen concentrations in *Synechocystis* sp. PCC 6803. *Biochim Biophys Acta*. 2007; 1767:161–169. [PubMed: 17274945]
207. Tsunoyama Y, Bernat G, Dyczmons NG, Schneider D, Rogner M. Multiple Rieske proteins enable short- and long-term light adaptation of *Synechocystis* sp. PCC 6803. *J Biol Chem*. 2009; 284:27875–27883. [PubMed: 19674969]
208. Peschek GA, Wastyn M, Fromwald S, Mayer B. Occurrence of heme O in photoheterotrophically growing, semi-anaerobic cyanobacterium *Synechocystis* sp. PCC6803. *FEBS Lett*. 1995; 371:89–93. [PubMed: 7672130]
209. Fromwald S, Zoder R, Wastyn M, Lubben M, Peschek GA. Extended heme promiscuity in the cyanobacterial cytochrome *c* oxidase: characterization of native complexes containing hemes A, O, and D, respectively. *Arch Biochem Biophys*. 1999; 367:122–128. [PubMed: 10375407]
210. Peschek GA, Obinger C, Paumann M. The respiratory chain of blue-green algae (cyanobacteria). *Physiol Plant*. 2004; 120:358–369. [PubMed: 15032833]
211. Hart SE, Schlarb-Ridley BG, Bendall DS, Howe CJ. Terminal oxidases of cyanobacteria. *Biochem Soc Trans*. 2005; 33:832–835. [PubMed: 16042609]
212. Zhang J, Oettmeier W, Gennis RB, Hellwig P. FTIR spectroscopic evidence for the involvement of an acidic residue in quinone binding in cytochrome *bd* from *Escherichia coli*. *Biochemistry*. 2002; 41:4612–4617. [PubMed: 11926823]
213. Yang K, Zhang J, Vakkasoglu AS, Hielscher R, Osborne JP, Hemp J, Miyoshi H, Hellwig P, Gennis RB. Glutamate 107 in subunit I of the cytochrome *bd* quinol oxidase from *Escherichia coli* is protonated and near the heme *d*/heme *b*₅₉₅ binuclear center. *Biochemistry*. 2007; 46:3270–3278. [PubMed: 17305364]
214. Mogi T, Endou S, Akimoto S, Morimoto-Tadokoro M, Miyoshi H. Glutamates 99 and 107 in transmembrane helix III of subunit I of cytochrome *bd* are critical for binding of the heme *b*₅₉₅-*d* binuclear center and enzyme activity. *Biochemistry*. 2006; 45:15785–15792. [PubMed: 17176101]
215. Belevich I, Bloch DA, Belevich N, Wikstrom M, Verkhovsky MI. Exploring the proton pump mechanism of cytochrome *c* oxidase in real time. *Proc Natl Acad Sci USA*. 2007; 104:2685–2690. [PubMed: 17293458]
216. Hastings SF, Ingledew WJ. A study of the stabilization of semiquinones by the *Escherichia coli* quinol oxidase cytochrome *bd*. *Biochem Soc Trans*. 1996; 24:131–132. [PubMed: 8674618]
217. Hastings SF, Kaysser TM, Jiang F, Salerno JC, Gennis RB, Ingledew WJ. Identification of a stable semiquinone intermediate in the purified and membrane bound ubiquinol oxidase-cytochrome *bd* from *Escherichia coli*. *Eur J Biochem*. 1998; 255:317–323. [PubMed: 9692934]
218. Rothery RA, Houston AM, Ingledew WJ. The respiratory chain of anaerobically grown *Escherichia coli*: Reactions with nitrite and oxygen. *J Gen Microbiol*. 1987; 133:3247–3255. [PubMed: 2833564]
219. Meinhardt SW, Gennis RB, Ohnishi T. EPR studies of the cytochrome-*d* complex of *Escherichia coli*. *Biochim Biophys Acta*. 1989; 975:175–184. [PubMed: 2544229]
220. Rothery R, Ingledew WJ. The cytochromes of anaerobically grown *Escherichia coli*. *Biochem J*. 1989; 262:437–443. [PubMed: 2549971]
221. Kahlow MA, Zuberi TM, Gennis RB, Loehr TM. Identification of a ferryl intermediate of *Escherichia coli* cytochrome *d* terminal oxidase by Resonance Raman spectroscopy. *Biochemistry*. 1991; 30:11485–11489. [PubMed: 1747367]
222. Hill BC, Hill JJ, Gennis RB. The room temperature reaction of carbon monoxide and oxygen with the cytochrome *bd* quinol oxidase from *Escherichia coli*. *Biochemistry*. 1994; 33:15110–15115. [PubMed: 7999770]
223. Ingledew WJ, Rothery RA, Gennis RB, Salerno JC. The orientation of the three haems of the *in situ* ubiquinol oxidase, cytochrome *bd*, of *Escherichia coli*. *Biochem J*. 1992; 282:255–259. [PubMed: 1311556]
224. Koland JG, Miller MJ, Gennis RB. Potentiometric analysis of the purified cytochrome *d* terminal oxidase complex from *Escherichia coli*. *Biochemistry*. 1984; 23:1051–1056.

225. Bloch DA, Borisov VB, Mogi T, Verkhovsky MI. Heme/heme redox interaction and resolution of individual optical absorption spectra of the hemes in cytochrome *bd* from *Escherichia coli*. *Biochim Biophys Acta*. 2009; 1787:1246–1253. [PubMed: 19450539]
226. Fang H, Lin R-J, Gennis RB. Location of heme axial ligands in the cytochrome *d* terminal oxidase complex of *Escherichia coli* determined by site-directed mutagenesis. *J Biol Chem*. 1989; 264:8026–8032. [PubMed: 2656671]
227. Spinner F, Cheesman MR, Thomson AJ, Kaysser T, Gennis RB, Peng Q, Peterson J. The haem *b*₅₅₈ component of the cytochrome *bd* quinol oxidase complex from *Escherichia coli* has histidine-methionine axial ligation. *Biochem J*. 1995; 308:641–644. [PubMed: 7772053]
228. Kaysser TM, Ghaim JB, Georgiou C, Gennis RB. Methionine-393 is an axial ligand of the heme *b*₅₅₈ component of the cytochrome *bd* ubiquinol oxidase from *Escherichia coli*. *Biochemistry*. 1995; 34:13491–13501. [PubMed: 7577938]
229. Zhang J, Barquera B, Gennis RB. Gene fusions with β -lactamase show that subunit I of the cytochrome *bd* quinol oxidase from *E. coli* has nine transmembrane helices with the O₂ reactive site near the periplasmic surface. *FEBS Lett*. 2004; 561:58–62. [PubMed: 15013751]
230. Sun J, Kahlow MA, Kaysser TM, Osborne JP, Hill JJ, Rohlfis RJ, Hille R, Gennis RB, Loehr TM. Resonance Raman spectroscopic identification of a histidine ligand of *b*₅₉₅ and the nature of the ligation of chlorin *d* in the fully reduced *Escherichia coli* cytochrome *bd* oxidase. *Biochemistry*. 1996; 35:2403–2412. [PubMed: 8652583]
231. Borisov VB, Gennis RB, Konstantinov AA. Interaction of cytochrome *bd* from *Escherichia coli* with hydrogen peroxide. *Biochemistry (Moscow)*. 1995; 60:231–239. (translated from *Biokhimiya* (in Russian) (1995), 60, 315–327).
232. Poole RK, Williams HD. Proposal that the function of the membrane-bound cytochrome *a*₁-like haemoprotein (cytochrome *b*-595) in *Escherichia coli* is a direct electron donation to cytochrome *d*. *FEBS Lett*. 1987; 217:49–52. [PubMed: 3036575]
233. Hata-Tanaka A, Matsuura K, Itoh S, Anraku Y. Electron flow and heme-heme interaction between cytochromes *b*-558, *b*-595 and *d* in a terminal oxidase of *Escherichia coli*. *Biochim Biophys Acta*. 1987; 893:289–295. [PubMed: 3040093]
234. D'mello R, Hill S, Poole RK. The Cytochrome *bd* quinol oxidase in *Escherichia coli* has an extremely high oxygen affinity and two-oxygen-binding haems: implications for regulation of activity *in vivo* by oxygen inhibition. *Microbiology*. 1996; 142:755–763. [PubMed: 8936304]
235. Timkovich R, Cork MS, Gennis RB, Johnson PY. Proposed structure of heme *d*, a prosthetic group of bacterial terminal oxidases. *J Am Chem Soc*. 1985; 107:6069–6075.
236. Poole RK, Kumar C, Salmon I, Chance B. The 650 nm chromophore in *Escherichia coli* is an 'Oxy-' or oxygenated compound, not the oxidized form of cytochrome oxidase *d*: A hypothesis. *J Gen Microbiol*. 1983; 129:1335–1344. [PubMed: 6311941]
237. Lorence RM, Gennis RB. Spectroscopic and quantitative analysis of the oxygenated and peroxy states of the purified cytochrome *d* complex of *Escherichia coli*. *J Biol Chem*. 1989; 264:7135–7140. [PubMed: 2540176]
238. Kahlow MA, Loehr TM, Zuberi TM, Gennis RB. The oxygenated complex of cytochrome *d* terminal oxidase: direct evidence for Fe-O₂ coordination in a chlorin-containing enzyme by Resonance Raman spectroscopy. *J Am Chem Soc*. 1993; 115:5845–5846.
239. Borisov VB, Smirnova IA, Krasnosel'skaya IA, Konstantinov AA. Oxygenated cytochrome *bd* from *Escherichia coli* can be converted into the oxidized form by lipophilic electron acceptors. *Biochemistry (Moscow)*. 1994; 59:437–443. (translated from *Biokhimiya* (in Russian) (1994), 59, 598–606).
240. Belevich I, Borisov VB, Konstantinov AA, Verkhovsky MI. Oxygenated complex of cytochrome *bd* from *Escherichia coli*: stability and photolability. *FEBS Lett*. 2005; 579:4567–4570. [PubMed: 16087180]
241. Belevich I, Borisov VB, Bloch DA, Konstantinov AA, Verkhovsky MI. Cytochrome *bd* from *Azotobacter vinelandii*: evidence for high-affinity oxygen binding. *Biochemistry*. 2007; 46:11177–11184. [PubMed: 17784736]
242. Azarkina N, Borisov V, Konstantinov AA. Spontaneous spectral changes of the reduced cytochrome *bd*. *FEBS Lett*. 1997; 416:171–174. [PubMed: 9369207]

243. Jiang FS, Zuberi TM, Cornelius JB, Clarkson RB, Gennis RB, Belford RL. Nitrogen and proton ENDOR of cytochrome *d*, hemein, and metmyoglobin in frozen solutions. *J Am Chem Soc.* 1993; 115:10293–10299.
244. Hirota S, Mogi T, Anraku Y, Gennis RB, Kitagawa T. Resonance Raman study on axial ligands of heme irons in cytochrome *bd*-type ubiquinol oxidase from *Escherichia coli*. *Biospectroscopy.* 1995; 1:305–311.
245. Hori H, Tsubaki M, Mogi T, Anraku Y. EPR study of NO complex of *bd*-type ubiquinol oxidase from *Escherichia coli*. *J Biol Chem.* 1996; 271:9254–9258. [PubMed: 8621585]
246. Mogi T. Probing the heme *d*-binding site in cytochrome *bd* quinol oxidase by site-directed mutagenesis. *J Biochem.* 2009; 145:763–770. [PubMed: 19254926]
247. Pudek MR, Bragg PD. Redox potentials of the cytochromes in the respiratory chain of aerobically grown *Escherichia coli*. *Arch Biochem Biophys.* 1976; 174:546–552. [PubMed: 779660]
248. Lorence RM, Miller MJ, Borochoy A, Faiman-Weinberg R, Gennis RB. Effects of pH and detergent on the kinetic and electrochemical properties of the purified cytochrome *d* terminal oxidase complex of *Escherichia coli*. *Biochim Biophys Acta.* 1984; 790:148–153. [PubMed: 6386051]
249. Junemann S, Wrigglesworth JM, Rich PR. Effects of *decyl*-aurachin D and reversed electron transfer in cytochrome *bd*. *Biochemistry.* 1997; 36:9323–9331. [PubMed: 9235974]
250. Trutko SM, Akimenko VK, Suzina NE, Anisimova LA, Shlyapnikov MG, Baskunov BP, Duda VI, Boronin AM. Involvement of the respiratory chain of gram-negative bacteria in the reduction of tellurite. *Arch Microbiol.* 2000; 173:178–186. [PubMed: 10763749]
251. Trutko SM, Suzina NE, Duda VI, Akimenko VK, Boronin AM. Participation of the bacterial respiratory chain in reduction of potassium tellurite. *Dokl Akad Nauk (in Russian).* 1998; 358:836–838.
252. Matsumoto Y, Muneyuki E, Fujita D, Sakamoto K, Miyoshi H, Yoshida M, Mogi T. Kinetic mechanism of quinol oxidation by cytochrome *bd* studied with ubiquinone-2 analogs. *J Biochem (Tokyo).* 2006; 139:779–788. [PubMed: 16672279]
253. Zhang J, Hellwig P, Osborne JP, Gennis RB. Arginine 391 in subunit I of the cytochrome *bd* quinol oxidase from *Escherichia coli* stabilizes the reduced form of the hemes and is essential for quinol oxidase activity. *J Biol Chem.* 2004; 279:53980–53987. [PubMed: 15475358]
254. Oden KL, Gennis RB. Isolation and characterization of a new class of cytochrome *d* terminal oxidase mutants of *Escherichia coli*. *J Bacteriol.* 1991; 173:6174–6183. [PubMed: 1655701]
255. Borisov VB. Interaction of *bd*-type quinol oxidase from *Escherichia coli* and carbon monoxide: Heme *d* binds CO with high affinity. *Biochemistry (Moscow).* 2008; 73:14–22. (translated from *Biokhimiya (in Russian)* (2008), 73, 18–28). [PubMed: 18294124]
256. Junemann S, Wrigglesworth JM. Stoichiometry of CO binding to the cytochrome *bd* complex of *Azotobacter vinelandii*. *Biochem Soc Trans.* 1993; 21:345S. [PubMed: 8131927]
257. Junemann S, Wrigglesworth JM. Cytochrome *bd* oxidase from *Azotobacter vinelandii*. Purification and quantitation of ligand binding to the oxygen reduction site. *J Biol Chem.* 1995; 270:16213–16220. [PubMed: 7608187]
258. Muntyan MS, Bloch DA, Drachev LA, Skulachev VP. Kinetics of CO binding to putative Na⁺-motive oxidases of the *o*-type from *Bacillus FTU* and of the *d*-type from *Escherichia coli*. *FEBS Lett.* 1993; 327:347–350. [PubMed: 8348962]
259. Junemann S, Rich PR, Wrigglesworth JM. CO flash photolysis of cytochrome *bd* from *Azotobacter vinelandii*. *Biochem Soc Trans.* 1995; 23:157S. [PubMed: 7672188]
260. Hubbard JAM, Hughes MN, Poole RK. Nitrite, but not silver, ions induce spectral changes in *Escherichia coli* cytochrome *d*. *FEBS Lett.* 1983; 164:241–243. [PubMed: 6317448]
261. Hubbard, JAM.; Hughes, MN.; Poole, RK. Poole, RK.; Dow, CS., editors. Academic Press; London: 1985. p. 231-236.
262. Bonner FT, Hughes MN, Poole RK, Scott RI. Kinetics of the reactions of trioxodinitrate and nitrite ions with cytochrome *d* in *Escherichia coli*. *Biochim Biophys Acta.* 1991; 1056:133–138. [PubMed: 1847082]
263. Kauffman HF, van Gelder BF, DerVartanian DV. Effect of ligands on cytochrome *d* from *Azotobacter vinelandii*. *J Bioenerg Biomembr.* 1980; 12:265–276. [PubMed: 6260768]

264. Junemann S, Wrigglesworth JM. Binding of NO to the oxygen reaction site of cytochrome *bd* from *Azotobacter vinelandii*. *Biochem Soc Trans*. 1996; 24:38S. [PubMed: 8674706]
265. Sarti P, Giuffre A, Forte E, Mastronicola D, Barone MC, Brunori M. Nitric oxide and cytochrome *c* oxidase: mechanisms of inhibition and NO degradation. *Biochem Biophys Res Commun*. 2000; 274:183–187. [PubMed: 10903916]
266. Lemon DD, Calhoun MW, Gennis RB, Woodruff WH. The gateway to the active site of heme-copper oxidases. *Biochemistry*. 1993; 32:11953–11956. [PubMed: 8218269]
267. Kauffman HF, Van Gelder BF. The respiratory chain of *Azotobacter vinelandii*. II. The effect of cyanide on cytochrome *d*. *Biochim Biophys Acta*. 1973; 314:276–283. [PubMed: 4356389]
268. Kauffman HF, Van Gelder BF. The respiratory chain of *Azotobacter vinelandii*. III. The effect of cyanide in the presence of substrates. *Biochim Biophys Acta*. 1974; 333:218–227. [PubMed: 19400034]
269. Pudek MR, Bragg PD. Inhibition by cyanide of the respiratory chain oxidases of *Escherichia coli*. *Arch Biochem Biophys*. 1974; 164:682–693. [PubMed: 4156636]
270. Pudek MR, Bragg PD. Reaction of cyanide with cytochrome *d* in respiratory particles from exponential phase *Escherichia coli*. *FEBS Lett*. 1975; 50:111–113. [PubMed: 1089559]
271. Poole, RK. Bacterial Energy Transduction. Anthony, C., editor. Academic Press; London: 1988. p. 231-291.
272. Krasnoselskaya I, Arutjunjan AM, Smirnova I, Gennis R, Konstantinov AA. Cyanide-reactive sites in cytochrome *bd* complex from *E. coli*. *FEBS Lett*. 1993; 327:279–283. [PubMed: 8348954]
273. Keyhani E, Minai-Tehrani D. The binding of cyanide to cytochrome *d* in intact cells, spheroplasts, membrane fragments and solubilized enzyme from *Salmonella typhimurium*. *Biochim Biophys Acta*. 2001; 1506
274. Kauffman HF, DerVartanian DV, van Gelder BF, Wampler J. EPR studies on cytochrome components in phosphorylating particles of *Azotobacter vinelandii*. *J Bioenerg*. 1975; 7:215–222.
275. Sun J, Osborne JP, Kahlow MA, Kaysser TM, Gennis RB, Loehr TM. Resonance Raman studies of *Escherichia coli* cytochrome *bd* oxidase. Selective enhancement of the three heme chromophores of the “as-isolated” enzyme and characterization of the cyanide adduct. *Biochemistry*. 1995; 34:12144–12151. [PubMed: 7547954]
276. Poole RK, Williams HD. Formation of the 680-nm-absorbing form of the cytochrome *bd* oxidase complex of *Escherichia coli* by reaction of hydrogen peroxide with the ferric form. *FEBS Lett*. 1988; 231:243–246. [PubMed: 3282921]
277. Borisov V, Gennis R, Konstantinov AA. Peroxide complex of cytochrome *bd*: Kinetics of generation and stability. *Biochem Mol Biol Int*. 1995; 37:975–982. [PubMed: 8624505]
278. Junemann S, Butterworth PJ, Wrigglesworth JM. A suggested mechanism for the catalytic cycle of cytochrome *bd* terminal oxidase based on kinetic analysis. *Biochemistry*. 1995; 34:14861–14867. [PubMed: 7578096]
279. Junemann S, Wrigglesworth JM. Antimycin inhibition of the cytochrome *bd* complex from *Azotobacter vinelandii* indicates the presence of a branched electron transfer pathway for the oxidation of ubiquinol. *FEBS Lett*. 1994; 345:198–202. [PubMed: 8200455]
280. Koland JG, Miller MJ, Gennis RB. Reconstitution of the membrane-bound, ubiquinone-dependent pyruvate oxidase respiratory chain of *Escherichia coli* with the cytochrome *d* terminal oxidase. *Biochemistry*. 1984; 23:445–453. [PubMed: 6367818]
281. Wikstrom M, Bogachev A, Finel M, Morgan JE, Puustinen A, Raitio M, Verkhovskaya M, Verkhovsky MI. Mechanism of proton translocation by the respiratory oxidases. The histidine cycle. *Biochim Biophys Acta*. 1994; 1187:106–111. [PubMed: 8075101]
282. Gibson Q, Greenwood C. Reactions of cytochrome oxidase with oxygen and carbon monoxide. *Biochem J*. 1963; 86:541–555. [PubMed: 13947736]
283. Borisov VB, Forte E, Sarti P, Giuffre A. Catalytic intermediates of cytochrome *bd* terminal oxidase at steady-state: Ferryl and oxy-ferrous species dominate. *Biochim Biophys Acta*. 2011; 1807:503–509. [PubMed: 21352800]
284. Mason MG, Nicholls P, Cooper CE. The steady-state mechanism of cytochrome *c* oxidase: redox interactions between metal centres. *Biochem J*. 2009; 422:237–246. [PubMed: 19534725]

285. Meunier B, Madgwick SA, Reil E, Oettmeier W, Rich PR. New inhibitors of the quinol oxidation sites of bacterial cytochromes *bo* and *bd*. *Biochemistry*. 1995; 34:1076–1083. [PubMed: 7827023]
286. Junemann S, Wrigglesworth JM. Inhibitors of electron transport in the cytochrome *bd* complex of *Azotobacter vinelandii*. *Biochem Soc Trans*. 1994; 22:287S. [PubMed: 7821546]
287. Jones CW, Redfearn ER. The cytochrome system of *Azotobacter vinelandii*. *Biochim Biophys Acta*. 1967; 143:340–353. [PubMed: 4292889]
288. Konishi K, Ouchi M, Kita K, Horikoshi I. Purification and properties of a cytochrome *b₅₆₀-d* complex, a terminal oxidase of the aerobic respiratory chain of *Photobacterium phosphoreum*. *J Biochem*. 1986; 99:1227–1236. [PubMed: 3011768]
289. Kavanagh EP, Callis JB, Edwards SE, Poole RK, Hill S. Redox poise and oxygenation of cytochrome *bd* in the diazotroph *Azotobacter vinelandii* assessed *in vivo* using diode-array reflectance spectrophotometry. *Microbiology*. 1998; 144(Pt 8):2271–80. [PubMed: 9720050]
290. Yang K, Borisov VB, Konstantinov AA, Gennis RB. The fully oxidized form of the cytochrome *bd* quinol oxidase from *E. coli* does not participate in the catalytic cycle: direct evidence from rapid kinetics studies. *FEBS Lett*. 2008; 582:3705–3709. [PubMed: 18823983]

Research highlights

- Physiological functions and genetics of cytochrome *bd* terminal oxidases reviewed.
- Structural and catalytic properties of cytochromes *bd* discussed.
- Phylogenetic analysis of cytochromes *bd* and their homologues presented.




Fig. 1. Respiratory oxygen reductases. The *bd*-family is subdivided into the A-subfamily (long Q-loop), B-subfamily (short Q-loop) and the cyanide insensitive oxygen reductases (CIO). These are subdivisions based entirely on spectroscopic and structural observations and are not phylogenetically defined clades.




Fig. 2.
Proposed cytochrome *bd* model.




Fig. 3. The *bd*-family of oxygen reductases. An unrooted phylogenetic tree showing the relationships between 815 sequences of cytochrome *bd* oxidases. Members with the Q-loop insertion (long Q-loop) are shown in red. All other members of the family have the “short Q-loop”. A number of members from the purple clade have been classified as cyanide insensitive oxidases (CIO) with a low content of heme *d*. Cytochromes *bd* from Archaea are shown in blue and form two related clades. In contrast, cytochrome *bd*-type oxygen reductases from the Firmicutes (yellow) and Bacteroidetes (green) are highlighted to demonstrate the sporadic distribution of enzymes within these phyla which resulted from horizontal gene transfer.




Fig. 4. Proposed topology of subunits I and II of cytochrome *bd-I* from *E. coli*. The axial ligands of heme b_{595} (H19) and heme b_{558} (H186 and M393) in subunit I are highlighted. The model is based on the data reported in [67,213,229].




Fig. 5. Scheme for electron and proton transfer pathways in cytochrome *bd-I* from *E. coli*. There are two protonatable groups, X_P and X_N redox-coupled to the heme *b*₅₉₅/heme *d* active site. A highly conserved E445 was proposed to be either the X_P group or the gateway in a channel that connects X_P with the cytoplasm or the periplasm [41]. A strictly conserved E107 is a part of the channel mediating proton transfer to X_N from the cytoplasm [48].




Fig. 6.
Top: Scheme for reaction of fully reduced cytochrome *bd* with O_2 . The three *rhombuses* represent hemes b_{558} , b_{595} , and d , respectively. The *minus sign* denotes that the heme is in the ferrous state. *Bottom:* Photolysis of CO from heme d in the fully reduced enzyme. Two different configurations of dissociated CO in the enzyme ($d \dots \dots CO_i$, $i=I, II$) are proposed [43]. The state ($d + CO$) denotes a state where CO escaped from the enzyme.




Fig. 7. Cytochrome *bd* catalytic cycle. The scheme is based on the reports of Junemann et al. [278], Kavanagh et al. [289], Matsumoto et al. [252], Belevich et al. [47], Yang et al. [290], and Borisov et al. [283]. Solid arrows show the natural catalytic reaction pathway. Dotted arrows indicate transitions that are not being part of the catalytic cycle can be observed experimentally. The **O** form of the enzyme is most likely not to be an intermediate of the catalytic cycle [290]. Intermediates populated at steady-state [283] are highlighted in grey.

Table 1

Effect of inhibitors on respiratory activity of cytochrome *bd*

Inhibitor	Bacterium			
	<i>E. coli</i> ^(a)	<i>B. stearo-thermophilus</i>	<i>A. vinelandii</i>	<i>Photobacterium phosphoreum</i>
KCN or NaCN	2 mM ^(b) [27]	0.5 mM ^(e) [68]	-	62 μM ^(b) [288]
NaN ₃	400 mM ^(b) [27]	8.2 mM ^(e) [68]	-	40 mM ^(b) [288]
H ₂ O ₂	120 mM ^(b) [27]	-	-	-
2- <i>n</i> -heptyl-4-hydroxyquinoline N-oxide (HOQNO)	7 μM ^(b) [27]	-	5–20 μM ^(d) [249]	8.2 μM ^(b) [288]
ZnSO ₄ or ZnCl ₂	60 μM ^(b) [27]	200 μM ^(e) [68]	-	2.7 μM ^(b) [288]
Piericidin A	15 μM ^(b) [27]	-	-	-
Antimicin A	50 μM, 80% ^(c) [285]	-	11 μM ^(d) [279,286]	-
Undecylhydroxydioxobenzothiazole (UHDBT)	20 μM, 18% ^(c) [285]	-	20 μM ^(d) [279,286]	-
(1,5-Dimethylhexyl)quinazolinamide	100 μM, 88% ^(c) [285]	-	-	-
(1-Methyldecyl)quinazolinamide	100 μM, 85% ^(c) [285]	-	-	-
Stigmatellin	200 μM, 14% ^(c) [285]	-	-	-
Nigericin	100 μM, 44% ^(c) [285]	-	-	-
Dibromothymoquinone	100 μM, 38% ^(c) [285]	-	-	-
Aurachin A	700 μM, 27% ^(c) [285]	-	-	-
Aurachin C	214 nM, 90% ^(c) [285]	-	-	-
Aurachin D	400 nM, 93% ^(c) [285]	-	-	-
<i>decyl</i> -aurachin D	-	-	13 nM ^(d) [249]	-
<i>p</i> -benzoquinone	-	120 μM ^(e) [68]	-	-
2,6-Dimethyl- <i>p</i> -benzoquinone	-	65 μM ^(e) [68]	-	-

Inhibitor	Bacterium			
	<i>E. coli</i> ^(a)	<i>B. stearo-thermophilus</i>	<i>A. vinelandii</i>	<i>Photobacterium phosphoreum</i>
Nitric oxide (NO)	100 nM (<i>d</i>) [106]	-	100 nM (<i>d</i>) [106]	-
Carbon monoxide (CO)	-	-	0.5–1 mM, 80% (<i>g</i>) [287]	-
Pentachlorophenol (PCP)	200 μM (<i>d</i>) [32]	-	-	-
2-Thenoyl trifluoroacetone (TTFA)	1 mM, 35% (<i>f</i>) [26]	-	-	-
Gramicidin S	5.3 μM (<i>b</i>) [145]	-	-	-

(*a*) Data are referred to cytochrome *bd*-I.

(*b*) IC₅₀ for ubiquinol-1 oxidase activity of the purified enzyme.

(*c*) Concentration and % inhibition of duroquinol oxidase activity of cytochrome *bd*-containing membranes.

(*d*) Inhibition constant (*K*₁) for ubiquinol-1 oxidase activity of the purified enzyme.

(*e*) IC₅₀ for duroquinol oxidase activity of the purified enzyme.

(*f*) Concentration and % inhibition of ubiquinol-1 oxidase activity of the purified enzyme.

(*g*) Concentration and % inhibition of ascorbate-2,6-dichlorophenolindophenol oxidase activity of cytochrome *bd*-containing particles.

Table 2Extinction coefficients used for determination of cytochrome *bd* concentration in *E. coli* and *A. vinelandii*.

Absorption spectrum	Heme	Wavelength pair (nm)	$\Delta\epsilon$ (mM ⁻¹ ·cm ⁻¹)	Reference
<i>E. coli</i> (cytochrome <i>bd</i>-1)				
<i>Difference:</i>				
Reduced minus 'as prepared'	<i>d</i>	628–607	10.8	[37]
	<i>d</i>	628–651 ^a	27.9	[36]
	<i>d</i>	628–649 ^a	18.8	[27]
	<i>b</i> ₅₅₈	561–580	21	[36]
	<i>b</i> ₅₉₅	595–606.5	1.9	[36]
	all	429–700 ^b	303	[36]
CO/reduced minus reduced	<i>d</i>	642–622	12.6	[27]
	<i>d</i>	643–623	13.2	[48]
<i>Absolute:</i>				
Reduced	<i>d</i>	628–670	25	[41]
'As prepared'	all	414–700 ^b	223	[36]
<i>A. vinelandii</i>				
<i>Difference:</i>				
Reduced minus 'as prepared'	<i>d</i>	628–605	9.5	[241]
	<i>d</i>	629–608	12	[257]
	<i>d</i>	629–650 ^a	27	[257]
CO/reduced minus reduced	<i>d</i>	622–642	18	[257]

^{a,b} These values cannot be recommended for determination of cytochrome *bd* concentration since

^a the 'as prepared' enzyme contains varying amounts of the ferrous heme *d*-oxy complex that absorbs at 649–651 nm, and

^b the intensity of the Soret band is variable depending on the purity of the preparation.

Table 3

Spectral properties of cytochrome *bd*-I from *E. coli*. Shown are wavelengths (nm) and extinction coefficients (in parentheses, $\text{mM}^{-1}\cdot\text{cm}^{-1}$) for “reduced-*minus*-oxidized” difference absorption spectra. Data are taken from reference [225].

	Heme <i>b</i>₅₅₈	Heme <i>b</i>₅₉₅	Heme <i>d</i>
Maxima	429.5 (90), 531.5 (5.8), 561 (17.2)	439 (113), 561.5 (8.2), 594 (5.3)	430 (30), 629 (18)
Minima	413 (-40), 497 (-4.3), 545 (~0)	400 (-37), 500 (-3.6), 643 (-1.18)	405 (-23), 468 (-6.3), 657.5 (-2.7), 739±2 (-2.4)
Isosbestic points	421, 450, 518, 573	422, 457, 535, 613	418.5, 449, 602, 648

Table 4

Kinetic and thermodynamic parameters for reaction of cytochrome *bd* with gaseous ligands at room temperature.

	<i>E. coli</i> (cytochrome <i>bd-I</i>)						<i>A. vinelandii</i>		
	O ₂		CO		NO		O ₂	CO	
	R ¹ -O ₂	R ³ -O ₂	R ¹ -CO	R ³ -CO	R ¹ -NO	R ³ -NO	R ³ -O ₂	R ¹ -CO	R ³ -CO
k_{on} (M ⁻¹ s ⁻¹)		2×10^9 ^{b,e}		8×10^7 ^{b,f}			2×10^9 ^h 2.8×10^8 ⁱ	1×10^8 ^g	1.5×10^8 ^g
k_{off} (s ⁻¹)	78 ^a		4.2 ^a	6 ^a	0.036 ^a	0.133 ^a			
K_d (nM)	280 ^c			80 ^d					

^a [107];

^b [222];

^c [240];

^d [255];

^e [47];

^f [43];

^g [249];

^h [241];

ⁱ [278].